Asial型FMDV复合表位免疫原的研制及免疫效果研究
|
摘要
口蹄疫(Foot-and-mouth Disease, FMD)作为一种全球范围内的重大动物疫病,已成为当前动物及其产品国际贸易的主要障碍。O、A、Asial型FMD是我国一直以来的防治重点,灭活疫苗在预防和控制FMD的过程中发挥着重要作用。
机体抵抗口蹄疫病毒(Foot-and-mouth Disease Virus, FMDV)感染过程中,依赖于中和抗体的体液免疫反应是最主要的。虽然灭活疫苗免疫能够产生高水平的中和抗体,但高水平的中和抗体并不是总能为机体提供完全的保护,同时CD4+T细胞在诱导机体体液抗体水平方面发挥着重要的作用,提示同时提高机体的体液免疫和细胞免疫对于FMD的预防更有意义。复合表位疫苗减少了疫苗中与免疫无关的成分,同时可对T、B细胞抗原表位进行不同组合,是实现口蹄疫体液免疫应答和细胞免疫应答的理想选择。FMDV主要是依靠接触和空气进行传播,黏膜免疫应答能够在黏膜部位产生大量的分泌性的sIgA,分泌性的sIgA不仅可以在第一时间中和病毒,而且可通过黏膜的方式进一步激活系统免疫反应,进而阻止病毒的侵入。所以有效的诱导黏膜部位产生sIgA是口蹄疫疫苗发展的新方向。
本研究人工设计了复合表位肽,并分别以乙型肝炎病毒核心抗原(HBcAg)和牛IgG2a Fc片段为载体,利用原核表达系统和毕赤酵母表达系统,制备三种复合表位免疫原pET28a-HBc-EB、 pET22b-EB-BIg和rGS115-pPICZA-HBc-EB,通过腹腔注射、口服和滴鼻三种途径分别对小鼠进行免疫,从体液免疫、细胞免疫和黏膜免疫水平对复合表位疫苗的免疫效果进行综合评价。
(1) Asial型FMDV复合表位免疫原的设计及合成
选取VP1上第140-160位、第200～211位两个B细胞表位和VP1上第20～40位、3A上第21～35两个T细胞表位为候选表位,并在其间引入合适的linker序列,构成了Asial型FMDV的复合表位。该复合表位肽通过linker序列GSGSG融合于HBcAg的第78～79位氨基酸(刺突位置),软件分析表明,Linker序列在表位之间形成柔性区域和转角,特别是序列(G4S)3的引入保证了两个B细胞表位的独立作用,而复合表位肽所在的HBc刺突位置具有较高的抗原性且大部分存在于表位部分,并有出现在分子表面的可能性,将融合有复合表位的HBc Ag序列优化后合成。
(2)复合表位免疫原在原核表达系统中的制备及腹腔免疫效果评价
1)复合表位免疫原在原核表达系统中的制备
以合成的质粒pUC57-simple-HBc-EB为模板,PCR扩增出目的基因,产物酶切后与pET28a连接,得到重组表达质粒pET28a-HBc-EB。以合成的含有牛IgG2a Fc片段基因的pUC57-simple-BIg质粒为模板,扩增出牛IgG2a Fc片段基因,并利用融合PCR方法与复合表位基因连接,酶切后与pET22b连接,得到重组表达质粒pET22b-EB-BIg。复性后的重组pET28a-HBc-EB在电镜下可观察到病毒样粒子的存在,而重组蛋白pET22b-EB-BIg也形成了类似免疫球蛋白单体的形式,能够与兔抗牛抗体直接结合。Western blot鉴定结果表明两免疫原均具备良好的抗原性,更为重要的是Dot ELISA结果显示复性后的复合表位免疫原能够与Asial型FMDV VP1构象表位抗体很好的结合,间接说明复合后的表位免疫原能够一定程度上折叠为类似于Asial型VP1蛋白构象型表位的抗原结构。
2)复合表位免疫原腹腔免疫效果评价
免疫后28d的检测结果表明,pET28a-HBc-EB组和pET22b-EB-BIg组小鼠抗体水平显著高于疫苗免疫组(P<0.01或P<0.05),pET28a-HBc-EB组的抗体水平显著高于pET22b-EB-BIg组(P<0.05); pET28a-HBc-EB组液相阻断抗体效价高于疫苗免疫组,为1:256-1:512;而pET22b-EB-BIg组液相阻断抗体效价为1：128～1：256,与灭活疫苗组相当；pET28a-HBc-EB组和pET22b-EB-BIg组的淋巴细胞刺激指数显著高于灭活疫苗免疫组(P<0.01)。pET28a-HBc-EB组和pET22b-EB-BIg组的CD4+/CD8+比值显著高于灭活疫苗组(P<0.01,P<0.05)。pET28a-HBc-EB组和pET22b-EB-BIg组小鼠脾细胞刺激后产生的IL-2和IFN-γ显著高于灭活疫苗组(P<0.01),pET28a-HBc-EB组IL-4和IL-10产生水平显著高于灭活疫苗组(P<0.05),而pET22b-EB-BIg组与灭活疫苗组无显著差异。表明Asial型FMDV多表位免疫原具有良好的免疫效果,既可刺激机体产生高水平的体液免疫,又可以刺激机体发生细胞免疫,其中以pET28a-HBc-EB组免疫效果最佳。
复合表位免疫原腹腔免疫较为理想的效果证实了复合表位免疫原的有效性,为口服免疫和滴鼻免疫提供了保证。
(3)复合表位免疫原在毕赤酵母表达系统中的制备及口服免疫效果评价
1)复合表位免疫原在毕赤酵母表达系统中的制备
本研究鉴于毕赤酵母具备真核细胞表达系统的修饰功能的特点,以期获得具有天然结构的复合表位免疫原。酶切重组质粒pET28a-HBc-EB,获得复合表位多肽基因,与pPICZA胞内表达载体连接,获得重组质粒pPICZA-HBc-EB;以本实验保存的含有Asial型FMDV全基因的质粒为模板,分别扩增病毒衣壳蛋白编码基因,并分别克隆于毕赤酵母表达载体pPICZA中,然后通过PCR方法在含有各表达盒两端引入酶切位点,各表达盒经酶切后依次将连入pPICZA载体中,最终构建酵母表达质粒pPICZA-vp031; Western blot和Dot ELISA鉴定结果表明表达产物具有良好的抗原性。
2)重组毕赤酵母以5×108CFU剂量口服免疫小鼠,免疫后28d检测结果表明,pPICZA-HBc-EB组和pPICZA-vpO31组抗体水平显著低于灭活疫苗免疫组(P<0.01)；液相阻断抗体效价为1：8～1：16；毕赤酵母免疫组小鼠黏膜冲洗液sIgA和特异性sIgA总量显著高于疫苗组(P<0.01); pPICZA-HBc-EB组和pPICZA-vp031组的黏膜特异性sIgA显著高于灭活疫苗组(P<0.01); pPICZA-HBc-EB组和pPICZA-vp031组淋巴细胞增殖指数均显著高于灭活疫苗免疫组(P<0.01),而pPICZA-HBc-EB组显著高于pPICZA-vpO31组(P<0.05)；灭活疫苗组CD4+/CD8+比值显著高于pPICZA-HBc-EB组和pPICZA-vp031组(P<0.01)：pPICZA-HBc-EB组小鼠脾细胞刺激后产生的IL-2和IFN-γ显著高于灭活疫苗组(P<0.01),而pPICZA-vp031组则与灭活疫苗组无显著差异(P>0.05),pPICZA-HBc-EB组和pPICZA-vp031组IL-4和IL-10水平与灭活疫苗组无显著差异(P>0.05)。说明口服重组酵母菌不仅可刺激机体产生体液免疫和细胞免疫,而且还能显著地诱导机体黏膜免疫。证实了复合表位免疫原通过口服免疫激发黏膜免疫的可行性。
(4)复合表位免疫原滴鼻免疫效果的评价
利用原核系统制备的复合表位疫苗对小鼠进行滴鼻免疫,免疫后28d pET22b-EB-BIg组抗体水平显著高于pET28a-HBc-EB组(P<0.01),显著低于灭活疫苗免疫组(P<0.01),且抗体上升趋势较为缓慢；液相阻断抗体效价低于1:8; pET22b-EB-BIg滴鼻免疫组黏膜冲洗液总sIgA水平、黏膜特异性sIgA抗体水平显著高于灭活疫苗组、pET28a-HBc-EB滴鼻免疫组(P<0.01)；pET22b-EB-BIg滴鼻免疫组的刺激指数显著高于其他各组(P<0.05)；pET22b-EB-BIg滴鼻免疫组CD4+/CD8+比值显著低于灭活疫苗免疫组(P<0.01)。上述结果说明pET22b-EB-BIg免疫后小鼠上支气管和肺部冲洗液、肠冲洗液和生殖道冲洗液中均有特异性sIgA的分泌,同时机体产生一定的体液免疫和细胞免疫,而pET28a-HBc-EB则无此效应,首次实践了靶向FcRn激发黏膜免疫的可行性,为FMD黏膜疫苗的制备提供一种新的思路。
Foot-and-mouth disease (FMD) is a highly contagious and economically devastating viral disease of cloven-hoofed animals worldwide. Thus, controlling the disease especially caused by the O, A and Asia1foot and mouth disease virus (FMDV) in China through regular vaccination and slaughter of infected and contact animals are very important. Currently, the conventional FMD inactivated vaccine has played an important role in controlling the disease.
Humoral immune response of neutralizing antibodies plays an important role in the anti-FMDV process. Production of high titres of neutralizing antibodies induced by the inactivated vaccine is not always protective in livestock. Stimulating CD4+T-cell responses is important for the induction of optimum antibody responses to inactivated vaccine. Therefore, it is essential to consider the efficacy and practical use of vaccines in order to induce an effective humoral immune response and cell-mediated immunity. The epitope vaccines combined with the T cell and B cell epitopes, which reduced the ingredients independent within the vaccines is the ideal choice to achieve high humoral and cellular immune response. The spread of FMD is mainly based on the close contact and the air. The mucosal immunity induces the mucous membrane to produce many slgA, which not only can neutralize the virus at the first time, but also induce system immune response. Therefore, effective in inducing the mucous membranes slgA is the new direction of development of the foot-and-mouth disease vaccine.
In this study, a multi-epitope peptide was designed, fused to HBcAg and Bovine IgG2a Fc, individually. The three multi-epitope immunogens pET28a-HBc-EB, pET22b-EB-BIg and rGS115-pPICZA-HBc-EB were expressed in E.coli and Pichia pastoris. The three multi-epitope immunogens were used to immune mice by intraperitoneal injection, oral and intranasal, then the immune effects were evaluated by humoral immunity, cellular immunity and mucosal immunity.
(1) Design and synthesis of Asial FMDV multi-epitope immunogen
In this study, two B cell epitopes (141-160aa and200-213aa) in VP1protein and the T cell epitopes (21-40aa in VP1and21-35aa in3A protein) were linked by the suitable linker sequence between them and synthesized as the candidate contents of the vaccine (the multi-epitopes designated as the EB). This EB sequences were inserted to the78to79amino acids of the HBcAg sequence with the linker GSGSG (spike position), and the multi-epitopes designated as the HBC-EB. Based on the software analysis, the linker sequence formed the flexible regions and corners between the epitopes, especially the sequence (G4S)3guaranteed the two B cell epitopes exist as the independent role. The HBc-EB had a high antigenicity and most of the multi-epitope expressing in the HBc spike position, which was possible in surface. Then, the HBC-EB with its optimized gene sequences was optimized and synthesized.
(2) Generation of multi-epitope immunogen and effects of immunity by intraperitoneal injection
1) Generation of multi-epitope immunogen in E.coli
The target gene was amplified by the PCR and the recombinant expression plasmid pET28a-HBc-EB was constructed. Based on the synthesized pUC57-simple-BIg plasmid as the template, the BIg gene was amplified and fused by the EB gene to generate the recombinant expression plasmid pET22b-EB-BIg. The recombinant plasmids were expressed in E.coli. Electron microscopy showed that the refolded protein pET28a-HBc-EB complex formed as virus-like particles. Western blot and Dot ELISA results confirmed that the recombinant proteins had great antigenicity, and the recombinant protein pET22b-EB-BIg reacted directly with Horseradish peroxidase-conjugated rabbit anti-bovine IgG antibody. The immunization strategy was done using the antigens based on the Asial FMDV multi-epitope immunogen.
2) Effects of immunity by intraperitoneal injection
The test was taken at28d after the mice immunized and the results showed that the antibody levels of the pET28a-HBc-EB group and pET22b-EB-BIg group were significantly higher than the inactivated vaccine group (P<0.01or P<0.05), the antibody levels of pET28a-HBc-EB group were significantly higher than the pET22b-EB-BIg group (P<0.05); The liquid phase blocking antibody titer of the pET22b-EB-BIg group was near vaccine group while pET28a-HBc-EB group higher than inactivated vaccine group, which was from1:256to1:512. T-lymphocyte proliferation assay was performed using the Cell Titer96aqueous one solution assay (MTS assay). The results showed that the stimulation index of the pET28a-HBc-EB group and pET22b-EB-BIg group were significantly higher than the inactivated vaccine group (P<0.01). The CD4+and CD8+T cell were detected by the Flow cytometry. The results showed that the CD4+/CD8+ratio of the pET28a-HBc-EB group and the pET22b-EB-Big group was significantly higher than the inactivated vaccine group (P<0.01and <0.05). The cytokine ELISA assay showed that the mouse spleen cells stimulated IL-2and IFN-gamma levels of the pET28a-HBc-EB group and pET22b-EB-BIg were significantly higher than those in the inactivated vaccine group (P<0.01); and the IL-4and IL-10levels of the pET28a-HBc-EB group were significantly higher than the inactivated vaccine group (P<0.05), while the difference between the pET22b-EB-BIg group and the inactivated vaccine was not significant. In conclusion, the Asial FMDV type multi-epitope immunogenic vaccines had the good immune effect, which stimulate the mice to generate high levels of humoral and cellular immunity, especially the pET28a-HBc-EB immunogen.
(3) Production of multi-epitope immunogen in Pichia pastoris and effects of immunity by oral
1) Production of multi-epitope immunogen in Pichia pastoris
In this study, as the Pichia pastoris has the characteristics of the eukaryotic cell expression system modification, we select Pichia pastoris to generate multi-epitope immunogen that has the natural structure. The multi-epitopes gene EB was digested from pET28a-HBc-EB and cloned into pPICZA, to construct the recombinant expression plasmid pPICZA-HBc-EB. Using the plasmids containing Asial FMDV gene prepared in our lab as the template, the genes of the three proteins were cloned into Pichia pastoris expression vector-pPICZA. Then the restriction enzyme sites were introduced into the expression cassette individually by PCR, which was ligated into pPICZA orderly to construct the pPICZA-vp031. Western blot and Dot ELISA showed that the recombinant expression products had great antigenicity.
2) Effects of immunity by oral
The mice were immunized by oral with recombinant Pichia pastoris at the dose of5×10s. The results showed that the antibody levels of the experimental group pPICZA-HBc-EB and pPICZA-vp031were significantly higher than pPICZA control group at28d post immunization (P<0.01), but significantly lower than inactivated vaccine group (P<0.01); the liquid phase blocking antibody titer was1:8to1:16. The mucosal sIgA levels of flushing fluid of the mice immunized with Pichia pastoris were significantly higher than inactivated vaccine group (P<0.01); and the mucosa-specific sIgA of the experimental group pPICZA-HBc-EB and pPICZA-vp031were significantly higher than inactivated vaccine group, pPICZA group (P<0.01). The stimulation index of pPICZA-HBc-EB group and pPICZA-vp031group were significantly higher than the inactivated vaccine group (P<0.01) and the pPICZA-HBc-EB group was higher than pPICZA-vp031group (P<0.05). The CD4+/CD8+ratio of the inactivated vaccine group were significantly higher than pPICZA-HBc-EB group and pPICZA-vp031group (P<0.01). The cytokine ELISA assay showed that the mouse spleen cells stimulated IL-2and IFN-gamma levels of pPICZA-HBc-EB group were significantly higher than those in the vaccine group (P<0.01), while the differences among the pPICZA-vp031group the inactivated vaccine group were not significant (P>0.05); the IL-4and IL-10levels of pPICZA-HBc-EB group and pPICZA-vp031group had no significant difference with the inactivated vaccine group (P>0.05). Taken together, the results indicated that the oral immunization with the Asial oral immunogen could not only stimulate the production of humoral and cellular immunity, but also significantly induce mucosal immunity.
(4) Effects of immunity by intranasal
The mice were immunized i.n. with the recombinant protein pET28a-HBc-EB and pET22b-EB-BIg.28d past first immunization, results showed that the antibody levels of the pET22b-EB-BIg group were significantly higher than the pET28a-HBc-EB group (P<0.01), significantly lower than the inactivated vaccine group (P<0.01), with lower the antibody grown trend; The liquid phase blocking antibody titer was down to1:8; However, the level of total sIgA and specific sIgA of the pET22b-EB-BIg group were significantly higher than the other groups (P<0.01); The stimulation index of the pET22b-EB-BIg group was significantly higher than the other groups (P<0.05); While, its CD4+/CD8+ratio was significantly lower than inactivated vaccine group (P<0.01). These results indicate that Bovine IgG2a Fc fragment fusion protein could stimulate both the humoral and cellular immune responses, which can induce mucosal immunity, although the overall strength is not high, while pET28a-HBc-EB did not, our work confirmed for the first time the feasibility of targeting the FcRn stimulate mucosal immune, which may provide a new way for preparing the FMD mucosal vaccine.
机体抵抗口蹄疫病毒(Foot-and-mouth Disease Virus, FMDV)感染过程中,依赖于中和抗体的体液免疫反应是最主要的。虽然灭活疫苗免疫能够产生高水平的中和抗体,但高水平的中和抗体并不是总能为机体提供完全的保护,同时CD4+T细胞在诱导机体体液抗体水平方面发挥着重要的作用,提示同时提高机体的体液免疫和细胞免疫对于FMD的预防更有意义。复合表位疫苗减少了疫苗中与免疫无关的成分,同时可对T、B细胞抗原表位进行不同组合,是实现口蹄疫体液免疫应答和细胞免疫应答的理想选择。FMDV主要是依靠接触和空气进行传播,黏膜免疫应答能够在黏膜部位产生大量的分泌性的sIgA,分泌性的sIgA不仅可以在第一时间中和病毒,而且可通过黏膜的方式进一步激活系统免疫反应,进而阻止病毒的侵入。所以有效的诱导黏膜部位产生sIgA是口蹄疫疫苗发展的新方向。
本研究人工设计了复合表位肽,并分别以乙型肝炎病毒核心抗原(HBcAg)和牛IgG2a Fc片段为载体,利用原核表达系统和毕赤酵母表达系统,制备三种复合表位免疫原pET28a-HBc-EB、 pET22b-EB-BIg和rGS115-pPICZA-HBc-EB,通过腹腔注射、口服和滴鼻三种途径分别对小鼠进行免疫,从体液免疫、细胞免疫和黏膜免疫水平对复合表位疫苗的免疫效果进行综合评价。
(1) Asial型FMDV复合表位免疫原的设计及合成
选取VP1上第140-160位、第200～211位两个B细胞表位和VP1上第20～40位、3A上第21～35两个T细胞表位为候选表位,并在其间引入合适的linker序列,构成了Asial型FMDV的复合表位。该复合表位肽通过linker序列GSGSG融合于HBcAg的第78～79位氨基酸(刺突位置),软件分析表明,Linker序列在表位之间形成柔性区域和转角,特别是序列(G4S)3的引入保证了两个B细胞表位的独立作用,而复合表位肽所在的HBc刺突位置具有较高的抗原性且大部分存在于表位部分,并有出现在分子表面的可能性,将融合有复合表位的HBc Ag序列优化后合成。
(2)复合表位免疫原在原核表达系统中的制备及腹腔免疫效果评价
1)复合表位免疫原在原核表达系统中的制备
以合成的质粒pUC57-simple-HBc-EB为模板,PCR扩增出目的基因,产物酶切后与pET28a连接,得到重组表达质粒pET28a-HBc-EB。以合成的含有牛IgG2a Fc片段基因的pUC57-simple-BIg质粒为模板,扩增出牛IgG2a Fc片段基因,并利用融合PCR方法与复合表位基因连接,酶切后与pET22b连接,得到重组表达质粒pET22b-EB-BIg。复性后的重组pET28a-HBc-EB在电镜下可观察到病毒样粒子的存在,而重组蛋白pET22b-EB-BIg也形成了类似免疫球蛋白单体的形式,能够与兔抗牛抗体直接结合。Western blot鉴定结果表明两免疫原均具备良好的抗原性,更为重要的是Dot ELISA结果显示复性后的复合表位免疫原能够与Asial型FMDV VP1构象表位抗体很好的结合,间接说明复合后的表位免疫原能够一定程度上折叠为类似于Asial型VP1蛋白构象型表位的抗原结构。
2)复合表位免疫原腹腔免疫效果评价
免疫后28d的检测结果表明,pET28a-HBc-EB组和pET22b-EB-BIg组小鼠抗体水平显著高于疫苗免疫组(P<0.01或P<0.05),pET28a-HBc-EB组的抗体水平显著高于pET22b-EB-BIg组(P<0.05); pET28a-HBc-EB组液相阻断抗体效价高于疫苗免疫组,为1:256-1:512;而pET22b-EB-BIg组液相阻断抗体效价为1：128～1：256,与灭活疫苗组相当；pET28a-HBc-EB组和pET22b-EB-BIg组的淋巴细胞刺激指数显著高于灭活疫苗免疫组(P<0.01)。pET28a-HBc-EB组和pET22b-EB-BIg组的CD4+/CD8+比值显著高于灭活疫苗组(P<0.01,P<0.05)。pET28a-HBc-EB组和pET22b-EB-BIg组小鼠脾细胞刺激后产生的IL-2和IFN-γ显著高于灭活疫苗组(P<0.01),pET28a-HBc-EB组IL-4和IL-10产生水平显著高于灭活疫苗组(P<0.05),而pET22b-EB-BIg组与灭活疫苗组无显著差异。表明Asial型FMDV多表位免疫原具有良好的免疫效果,既可刺激机体产生高水平的体液免疫,又可以刺激机体发生细胞免疫,其中以pET28a-HBc-EB组免疫效果最佳。
复合表位免疫原腹腔免疫较为理想的效果证实了复合表位免疫原的有效性,为口服免疫和滴鼻免疫提供了保证。
(3)复合表位免疫原在毕赤酵母表达系统中的制备及口服免疫效果评价
1)复合表位免疫原在毕赤酵母表达系统中的制备
本研究鉴于毕赤酵母具备真核细胞表达系统的修饰功能的特点,以期获得具有天然结构的复合表位免疫原。酶切重组质粒pET28a-HBc-EB,获得复合表位多肽基因,与pPICZA胞内表达载体连接,获得重组质粒pPICZA-HBc-EB;以本实验保存的含有Asial型FMDV全基因的质粒为模板,分别扩增病毒衣壳蛋白编码基因,并分别克隆于毕赤酵母表达载体pPICZA中,然后通过PCR方法在含有各表达盒两端引入酶切位点,各表达盒经酶切后依次将连入pPICZA载体中,最终构建酵母表达质粒pPICZA-vp031; Western blot和Dot ELISA鉴定结果表明表达产物具有良好的抗原性。
2)重组毕赤酵母以5×108CFU剂量口服免疫小鼠,免疫后28d检测结果表明,pPICZA-HBc-EB组和pPICZA-vpO31组抗体水平显著低于灭活疫苗免疫组(P<0.01)；液相阻断抗体效价为1：8～1：16；毕赤酵母免疫组小鼠黏膜冲洗液sIgA和特异性sIgA总量显著高于疫苗组(P<0.01); pPICZA-HBc-EB组和pPICZA-vp031组的黏膜特异性sIgA显著高于灭活疫苗组(P<0.01); pPICZA-HBc-EB组和pPICZA-vp031组淋巴细胞增殖指数均显著高于灭活疫苗免疫组(P<0.01),而pPICZA-HBc-EB组显著高于pPICZA-vpO31组(P<0.05)；灭活疫苗组CD4+/CD8+比值显著高于pPICZA-HBc-EB组和pPICZA-vp031组(P<0.01)：pPICZA-HBc-EB组小鼠脾细胞刺激后产生的IL-2和IFN-γ显著高于灭活疫苗组(P<0.01),而pPICZA-vp031组则与灭活疫苗组无显著差异(P>0.05),pPICZA-HBc-EB组和pPICZA-vp031组IL-4和IL-10水平与灭活疫苗组无显著差异(P>0.05)。说明口服重组酵母菌不仅可刺激机体产生体液免疫和细胞免疫,而且还能显著地诱导机体黏膜免疫。证实了复合表位免疫原通过口服免疫激发黏膜免疫的可行性。
(4)复合表位免疫原滴鼻免疫效果的评价
利用原核系统制备的复合表位疫苗对小鼠进行滴鼻免疫,免疫后28d pET22b-EB-BIg组抗体水平显著高于pET28a-HBc-EB组(P<0.01),显著低于灭活疫苗免疫组(P<0.01),且抗体上升趋势较为缓慢；液相阻断抗体效价低于1:8; pET22b-EB-BIg滴鼻免疫组黏膜冲洗液总sIgA水平、黏膜特异性sIgA抗体水平显著高于灭活疫苗组、pET28a-HBc-EB滴鼻免疫组(P<0.01)；pET22b-EB-BIg滴鼻免疫组的刺激指数显著高于其他各组(P<0.05)；pET22b-EB-BIg滴鼻免疫组CD4+/CD8+比值显著低于灭活疫苗免疫组(P<0.01)。上述结果说明pET22b-EB-BIg免疫后小鼠上支气管和肺部冲洗液、肠冲洗液和生殖道冲洗液中均有特异性sIgA的分泌,同时机体产生一定的体液免疫和细胞免疫,而pET28a-HBc-EB则无此效应,首次实践了靶向FcRn激发黏膜免疫的可行性,为FMD黏膜疫苗的制备提供一种新的思路。
Foot-and-mouth disease (FMD) is a highly contagious and economically devastating viral disease of cloven-hoofed animals worldwide. Thus, controlling the disease especially caused by the O, A and Asia1foot and mouth disease virus (FMDV) in China through regular vaccination and slaughter of infected and contact animals are very important. Currently, the conventional FMD inactivated vaccine has played an important role in controlling the disease.
Humoral immune response of neutralizing antibodies plays an important role in the anti-FMDV process. Production of high titres of neutralizing antibodies induced by the inactivated vaccine is not always protective in livestock. Stimulating CD4+T-cell responses is important for the induction of optimum antibody responses to inactivated vaccine. Therefore, it is essential to consider the efficacy and practical use of vaccines in order to induce an effective humoral immune response and cell-mediated immunity. The epitope vaccines combined with the T cell and B cell epitopes, which reduced the ingredients independent within the vaccines is the ideal choice to achieve high humoral and cellular immune response. The spread of FMD is mainly based on the close contact and the air. The mucosal immunity induces the mucous membrane to produce many slgA, which not only can neutralize the virus at the first time, but also induce system immune response. Therefore, effective in inducing the mucous membranes slgA is the new direction of development of the foot-and-mouth disease vaccine.
In this study, a multi-epitope peptide was designed, fused to HBcAg and Bovine IgG2a Fc, individually. The three multi-epitope immunogens pET28a-HBc-EB, pET22b-EB-BIg and rGS115-pPICZA-HBc-EB were expressed in E.coli and Pichia pastoris. The three multi-epitope immunogens were used to immune mice by intraperitoneal injection, oral and intranasal, then the immune effects were evaluated by humoral immunity, cellular immunity and mucosal immunity.
(1) Design and synthesis of Asial FMDV multi-epitope immunogen
In this study, two B cell epitopes (141-160aa and200-213aa) in VP1protein and the T cell epitopes (21-40aa in VP1and21-35aa in3A protein) were linked by the suitable linker sequence between them and synthesized as the candidate contents of the vaccine (the multi-epitopes designated as the EB). This EB sequences were inserted to the78to79amino acids of the HBcAg sequence with the linker GSGSG (spike position), and the multi-epitopes designated as the HBC-EB. Based on the software analysis, the linker sequence formed the flexible regions and corners between the epitopes, especially the sequence (G4S)3guaranteed the two B cell epitopes exist as the independent role. The HBc-EB had a high antigenicity and most of the multi-epitope expressing in the HBc spike position, which was possible in surface. Then, the HBC-EB with its optimized gene sequences was optimized and synthesized.
(2) Generation of multi-epitope immunogen and effects of immunity by intraperitoneal injection
1) Generation of multi-epitope immunogen in E.coli
The target gene was amplified by the PCR and the recombinant expression plasmid pET28a-HBc-EB was constructed. Based on the synthesized pUC57-simple-BIg plasmid as the template, the BIg gene was amplified and fused by the EB gene to generate the recombinant expression plasmid pET22b-EB-BIg. The recombinant plasmids were expressed in E.coli. Electron microscopy showed that the refolded protein pET28a-HBc-EB complex formed as virus-like particles. Western blot and Dot ELISA results confirmed that the recombinant proteins had great antigenicity, and the recombinant protein pET22b-EB-BIg reacted directly with Horseradish peroxidase-conjugated rabbit anti-bovine IgG antibody. The immunization strategy was done using the antigens based on the Asial FMDV multi-epitope immunogen.
2) Effects of immunity by intraperitoneal injection
The test was taken at28d after the mice immunized and the results showed that the antibody levels of the pET28a-HBc-EB group and pET22b-EB-BIg group were significantly higher than the inactivated vaccine group (P<0.01or P<0.05), the antibody levels of pET28a-HBc-EB group were significantly higher than the pET22b-EB-BIg group (P<0.05); The liquid phase blocking antibody titer of the pET22b-EB-BIg group was near vaccine group while pET28a-HBc-EB group higher than inactivated vaccine group, which was from1:256to1:512. T-lymphocyte proliferation assay was performed using the Cell Titer96aqueous one solution assay (MTS assay). The results showed that the stimulation index of the pET28a-HBc-EB group and pET22b-EB-BIg group were significantly higher than the inactivated vaccine group (P<0.01). The CD4+and CD8+T cell were detected by the Flow cytometry. The results showed that the CD4+/CD8+ratio of the pET28a-HBc-EB group and the pET22b-EB-Big group was significantly higher than the inactivated vaccine group (P<0.01and <0.05). The cytokine ELISA assay showed that the mouse spleen cells stimulated IL-2and IFN-gamma levels of the pET28a-HBc-EB group and pET22b-EB-BIg were significantly higher than those in the inactivated vaccine group (P<0.01); and the IL-4and IL-10levels of the pET28a-HBc-EB group were significantly higher than the inactivated vaccine group (P<0.05), while the difference between the pET22b-EB-BIg group and the inactivated vaccine was not significant. In conclusion, the Asial FMDV type multi-epitope immunogenic vaccines had the good immune effect, which stimulate the mice to generate high levels of humoral and cellular immunity, especially the pET28a-HBc-EB immunogen.
(3) Production of multi-epitope immunogen in Pichia pastoris and effects of immunity by oral
1) Production of multi-epitope immunogen in Pichia pastoris
In this study, as the Pichia pastoris has the characteristics of the eukaryotic cell expression system modification, we select Pichia pastoris to generate multi-epitope immunogen that has the natural structure. The multi-epitopes gene EB was digested from pET28a-HBc-EB and cloned into pPICZA, to construct the recombinant expression plasmid pPICZA-HBc-EB. Using the plasmids containing Asial FMDV gene prepared in our lab as the template, the genes of the three proteins were cloned into Pichia pastoris expression vector-pPICZA. Then the restriction enzyme sites were introduced into the expression cassette individually by PCR, which was ligated into pPICZA orderly to construct the pPICZA-vp031. Western blot and Dot ELISA showed that the recombinant expression products had great antigenicity.
2) Effects of immunity by oral
The mice were immunized by oral with recombinant Pichia pastoris at the dose of5×10s. The results showed that the antibody levels of the experimental group pPICZA-HBc-EB and pPICZA-vp031were significantly higher than pPICZA control group at28d post immunization (P<0.01), but significantly lower than inactivated vaccine group (P<0.01); the liquid phase blocking antibody titer was1:8to1:16. The mucosal sIgA levels of flushing fluid of the mice immunized with Pichia pastoris were significantly higher than inactivated vaccine group (P<0.01); and the mucosa-specific sIgA of the experimental group pPICZA-HBc-EB and pPICZA-vp031were significantly higher than inactivated vaccine group, pPICZA group (P<0.01). The stimulation index of pPICZA-HBc-EB group and pPICZA-vp031group were significantly higher than the inactivated vaccine group (P<0.01) and the pPICZA-HBc-EB group was higher than pPICZA-vp031group (P<0.05). The CD4+/CD8+ratio of the inactivated vaccine group were significantly higher than pPICZA-HBc-EB group and pPICZA-vp031group (P<0.01). The cytokine ELISA assay showed that the mouse spleen cells stimulated IL-2and IFN-gamma levels of pPICZA-HBc-EB group were significantly higher than those in the vaccine group (P<0.01), while the differences among the pPICZA-vp031group the inactivated vaccine group were not significant (P>0.05); the IL-4and IL-10levels of pPICZA-HBc-EB group and pPICZA-vp031group had no significant difference with the inactivated vaccine group (P>0.05). Taken together, the results indicated that the oral immunization with the Asial oral immunogen could not only stimulate the production of humoral and cellular immunity, but also significantly induce mucosal immunity.
(4) Effects of immunity by intranasal
The mice were immunized i.n. with the recombinant protein pET28a-HBc-EB and pET22b-EB-BIg.28d past first immunization, results showed that the antibody levels of the pET22b-EB-BIg group were significantly higher than the pET28a-HBc-EB group (P<0.01), significantly lower than the inactivated vaccine group (P<0.01), with lower the antibody grown trend; The liquid phase blocking antibody titer was down to1:8; However, the level of total sIgA and specific sIgA of the pET22b-EB-BIg group were significantly higher than the other groups (P<0.01); The stimulation index of the pET22b-EB-BIg group was significantly higher than the other groups (P<0.05); While, its CD4+/CD8+ratio was significantly lower than inactivated vaccine group (P<0.01). These results indicate that Bovine IgG2a Fc fragment fusion protein could stimulate both the humoral and cellular immune responses, which can induce mucosal immunity, although the overall strength is not high, while pET28a-HBc-EB did not, our work confirmed for the first time the feasibility of targeting the FcRn stimulate mucosal immune, which may provide a new way for preparing the FMD mucosal vaccine.
引文
[1]ALEXANDERSEN S, MO WAT N. Foot-and-mouth disease:host range and pathogenesis[J]. Curr Top Microbiol Immunol,2005,288:9-42.
[2]谢庆阁.口蹄疫[M].北京：中国农业出版社,2004.
[3]毕应佐.口蹄疫[M].广州：广东科技出版社,2005.
[4]MORT M, CONVERY I, BAXTER J, et al. Psychosocial effects of the 2001 UK foot and mouth disease epidemic in a rural population:qualitative diary based study[J]. BMJ,2005,331(7527):1234.
[5]KNOWLES N J, SAMUEL A R. Molecular epidemiology of foot-and-mouth disease virus[J]. Virus Res,2003,91(1):65-80.
[6]KITCHING R P. Global epidemiology and prospects for control of foot-and-mouth disease[J]. Curr Top Microbiol Immunol,2005,288:133-148.
[7]CARROLL A R, Rowlands D J, Clarke B E. The complete nucleotide sequence of the RNA coding for the primary translation product of foot and mouth disease virus[J]. Nucleic Acids Res, 1984,12(5):2461-2472.
[8]BELSHAM G J. Distinctive features of foot-and-mouth disease virus, a member of the picornavirus family; aspects of virus protein synthesis, protein processing and structure[J]. Prog Biophys Mol Biol, 1993,60(3):241-260.
[9]DOMINGO E, BARANOWSKI E, ESCARMIS C, et al. Foot-and-mouth disease virus[J]. Comp Immunol Microbiol Infect Dis,2002,25(5-6):297-308.
[10]PFAFF E, THIEL H J, BECK E, et al. Analysis of neutralizing epitopes on foot-and-mouth disease virus[J]. J Virol,1988,62(6):2033-2040.
[11]BUTCHAIAH G, MORGAN D O. Neutralization antigenic sites on type Asia-1 foot-and-mouth disease virus defined by monoclonal antibody-resistant variants[J]. Virus Res,1997,52(2):183-194.
[12]SANTINA GRAZIOLI F F E B. Mapping of neutralising sites on FMD virus type Asial and relationships with sites described in other serotypes[J]. Report of the Session of the Research Group of theStanding Committee of the European Commission of Footand Mouth Disease,2003,Appendix (44):277-287.
[13]GARABED R B, JOHNSON W O, THURMOND M C. Analytical epidemiology of genomic variation among Pan Asia strains of foot-and-mouth disease virus [J]. Transbound Emerg Dis, 2009,56(4):142-156.
[14]RANA S K, BAGCHI T. Partial sequence analysis of VP1 of Indian isolates of foot-and-mouth disease virus type Asia-1 [J]. Virus Genes,2008,37(1):60-68.
[15]BARNETT P V, OULDRIDGE E J, ROWLANDS D J, et al. Neutralizing epitopes of type O foot-and-mouth disease virus. I. Identification and characterization of three functionally independent, conformational sites[J]. J Gen Virol,1989,70 (Pt 6):1483-1491.
[16]CROWTHER J R, FARIAS S, CARPENTER W C, et al. Identification of a fifth neutralizable site on type O foot-and-mouth disease virus following characterization of single and quintuple monoclonal antibody escape mutants[J]. J Gen Virol,1993,74 (Pt 8):1547-1553.
[17]SAIZ J C, GONZALEZ M J, BORCA M V, et al. Identification of neutralizing antigenic sites on VP1 and VP2 of type A5 foot-and-mouth disease virus, defined by neutralization-resistant variants[J]. J Virol, 1991,65(5):2518-2524.
[18]THOMAS A A, WOORTMEIJER R J, PUIJK W, et al. Antigenic sites on foot-and-mouth disease virus type A10[J]. J Virol,1988,62(8):2782-2789.
[19]COLLEN T, DIMARCHI R, DOEL T R. A T cell epitope in VP1 of foot-and-mouth disease virus is immunodominant for vaccinated cattle[J]. J Immunol,1991,146(2):749-755.
[20]ZAMORANO P, WIGDOROVITZ A, CHAHER M T, et al. Recognition of B and T cell epitopes by cattle immunized with a synthetic peptide containing the major immunogenic site of VP1 FMDV 01 Campos[J]. Virology,1994,201(2):383-387.
[21]VAN LIEROP M J, WAGENAAR J P, VAN NOORT J M, ET AL. Sequences derived from the highly antigenic VP1 region 140 to 160 of foot-and-mouth disease virus do not prime for a bovine T-cell response against intact virus[J]. J Virol,1995,69(7):4511-4514.
[22]杨志军.含T细胞表位和B细胞表位的抗0型FMDV基因工程疫苗诱导豚鼠产生免疫反应[J].2000.
[23]FOSTER M, COOK A, CEDILLO L, et al. Serological and cellular immune responses to non-structural proteins in animals infected with FMDV[J]. Vet Q,1998,20 Suppl 2:S28-S30.
[24]BLANCO E, GARCIA-BRIONES M, SANZ-PARRA A, et al. Identification of T-cell epitopes in nonstructural proteins of foot-and-mouth disease virus[J]. J Virol,2001,75(7):3164-3174.
[25]GERNER W, DENYER M S, TAKAMATSU H H, et al. Identification of novel foot-and-mouth disease virus specific T-cell epitopes in c/c and d/d haplotype miniature swine[J]. Virus Res, 2006,121(2):223-228.
[26]SUTMOLLER P, MCVICAR J W, COTTRAL G E. The epizootiological importance of foot-and-mouth disease carriers. I. Experimentally produced foot-and-mouth disease carriers in susceptible and immune cattle[J]. Arch Gesamte Virusforsch,1968,23(3):227-235.
[27]VALARCHER J F, KNOWLES N J, FERRIS N P, et al. Recent spread of FMD virus serotype Asia 1[J]. Vet Rec,2005,157(1):30.
[28]王世若,王兴龙.现代动物免疫学[M].吉林科学技术出版社,1999.
[29]阴天榜,刘兴友.家禽免疫学[M].北京：中国农业科技出版社,1999.
[30]罗红林,黄维义.动物黏膜免疫及其细胞因子[J].吉林畜牧兽医,2004,5：19-21.
[31]KUNISAWA J, FUKUYAMA S, KIYONO H. Mucosa-associated lymphoid tissues in the aerodigestive tract:their shared and divergent traits and their importance to the orchestration of the mucosal immune system[J]. Curr Mol Med,2005,5(6):557-572.
[32]马玉龙,许梓荣.肠道黏膜免疫研究进展[J].中国畜牧杂志,2004,31.
[33]NEUTRA M R. Current concepts in mucosal immunity. V Role of M cells in transepithelial transport of antigens and pathogens to the mucosal immune system[J]. Am J Physiol,1998,274(5 Pt 1):G785-G791.
[34JRODRIGUEZ A, ROTTENBERG M, TJARNLUND A, et al. Immunoglobulin A and CD8 T-cell mucosal immune defenses protect against intranasal infection with Chlamydia pneumoniae[J]. Scand J Immunol,2006,63(3):177-183.
[35]YASUDA Y, ISAKA M, TANIGUCHI T, et al. Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies[J]. Vaccine, 2003,21 (21-22):2954-2963.
[36]FREYTAG L C, CLEMENTS J D. Bacterial toxins as mucosal adjuvants[J]. Curr Top Microbiol Immunol,1999,236:215-236.
[37]BAGLEY K C, ABDELWAHAB S F, TUSKAN R G, et al. Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway[J]. Infect Immun,2002,70(10):5533-5539.
[38]SHREEDHAR V K, KELSALL B L, NEUTRA M R. Cholera toxin induces migration of dendritic cells from the subepithelial dome region to T-and B-cell areas of Peyer's patches[J]. Infect Immun, 2003,71(1):504-509.
[39]张小飞,杨倩.黏膜免疫佐剂的研究进展[J].免疫学杂志,2004,20(3)：62-65.
[40]BOYAKA P N, MARINARO M, JACKSON R J, et al. IL-12 is an effective adjuvant for induction of mucosal immunity[J]. J Immunol,1999,162(1):122-128.
[41]HUBER V C, ARULANANDAM B P, ARNABOLDI P M, et al. Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity[J]. Int Immunopharmacol,2003,3(6):801-809.
[42]PROIETTI E, BRACCI L, PUZELLI S, et al. Type IIFN as a natural adjuvant for a protective immune response:lessons from the influenza vaccine model[J]. J Immunol,2002,169(1):375-383.
[43]PLAYFAIR J H, DE SOUZA J B. Recombinant gamma interferon is a potent adjuvant for a malaria vaccine in mice[J]. Clin Exp Immunol,1987,67(1):5-10.
[44]BRADNEY C P, SEMPOWSKI G D, LIAO H X, et al. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization [J]. J Virol,2002,76(2):517-524.
[45]TELONI R, VON HUNOLSTEIN C, MARIOTTI S, et al. Antibody classes & subclasses induced by mucosal immunization of mice with Streptococcus pyogenes M6 protein & oligodeoxynucleotides containing CpG motifs[J]. Indian J Med Res,2004,119 Suppl:126-130.
[46]GALLICHAN W S, WOOLSTENCROFT R N, GUARASCI T, et al. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract[J], J Immunol,2001,166(5):3451-3457.
[47]STEINMAN R M, COHN Z A. The interaction of soluble horseradish peroxidase with mouse peritoneal macrophages in vitro[J]. J Cell Biol,1972,55(1):186-204.
[48]STEINMAN R M, COHN Z A. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution[J]. J Exp Med,1973,137(5):1142-1162.
[49]NUSSENZWEIG M C, STEINMAN R M, GUTCHINOV B, et al. Dendritic cells are accessory cells for the development of anti-trinitrophenyl cytotoxic T lymphocytes[J]. J Exp Med, 1980,152(4):1070-1084.
[50]MARASKOVSKY E, BRASEL K, TEEPE M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice:multiple dendritic cell subpopulations identified[J]. J Exp Med,1996,184(5):1953-1962.
[51]LYMAN S D, JAMES L, VANDEN B T, et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor:a proliferative factor for primitive hematopoietic cells[J]. Cell,1993,75(6):1157-1167.
[52]HUNG C F, HSU K F, CHENG W F, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand[J]. Cancer Res,2001,61(3):1080-1088.
[53]MOORE A C, KONG W P, CHAKRABARTI B K, et al. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice[J]. J Virol, 2002,76(1):243-250.
[54]KATAOKA K, MCGHEE J R, KOBAYASHI R, et al. Nasal Flt3 ligand cDNA elicits CD1 lc+CD8+ dendritic cells for enhanced mucosal immunity[J]. J Immunol,2004,172(6):3612-3619.
[55]SEKINE S, KATAOKA K, FUKUYAMA Y, et al. A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration[J]. J Immunol,2008,180(12):8126-8134.
[56]GHETIE V, WARD E S. Multiple roles for the major histocompatibility complex class I-related receptor FcRn[J]. Annu Rev Immunol,2000,18:739-766.
[57]HE W, LADINSKY M S, HUEY-TUBMAN K E, et al. FcRn-mediated antibody transport across epithelial cells revealed by electron tomography[J]. Nature,2008,455(7212):542-546.
[58]DICKINSON B L, BADIZADEGAN K, WU Z, et al. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line[J]. J Clin Invest,1999,104(7):903-911.
[59]ROOPENIAN D C, AKILESH S. FcRn:the neonatal Fc receptor comes of age[J]. Nat Rev Immunol, 2007,7(9):715-725.
[60]BAKER K, QIAO S W, KUO T, et al. Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn[J]. Semin Immunopathol,2009,31(2):223-236.
[61]YOSHIDA M, KOBAYASHI K, KUO T T, et al. Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria[J]. J Clin Invest,2006,116(8):2142-2151.
[62]SIMISTER N E, MOSTOV K E. An Fc receptor structurally related to MHC class I antigens[J]. Nature, 1989,337(6203):184-187.
[63]ROOPENIAN D C, AKILESH S. FcRn:the neonatal Fc receptor comes of age[J]. Nat Rev Immunol, 2007,7(9):715-725.
[64]BAKER K, QIAO S W, KUO T, et al. Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn[J]. Semin Immunopathol,2009,31(2):223-236.
[65]CHAUDHURY C, MEHNAZ S, ROBINSON J M, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan[J]. J Exp Med, 2003,197(3):315-322.
[66]DUMONT J A, BITONTI A J, CLARK D, et al. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway[J]. J Aerosol Med, 2005,18(3):294-303.
[67]STIRLING C M, CHARLESTON B, TAKAMATSU H, et al. Characterization of the porcine neonatal Fc receptor--potential use for trans-epithelial protein delivery[J]. Immunology,2005,114(4):542-553.
[68]YE L, ZENG R, BAI Y, et al. Efficient mucosal vaccination mediated by the neonatal Fc receptor[J]. Nat Biotechnol,2011,29(2):158-163.
[69]BOCKMAN D E, COOPER M D. Pinocytosis by epithelium associated with lymphoid follicles in the bursa of Fabricius, appendix, and Peyer's patches. An electron microscopic study[J]. Am J Anat, 1973,136(4):455-477.
[70]FARSTAD I N, HALSTENSEN T S, FAUSA O, et al. Heterogeneity of M-cell-associated B and T cells in human Peyer's patches[J]. Immunology,1994,83(3):457-464.
[71]GEBERT A, ROTHKOTTER H J, PABST R. M cells in Peyer's patches of the intestine[J]. Int Rev Cytol,1996,167:91-159.
[72]NEUTRA M R, FREY A, KRAEHENBUHL J P. Epithelial M cells:gateways for mucosal infection and immunization[J]. Cell,1996,86(3):345-348.
[73]OWEN R L, JONES A L. Epithelial cell specialization within human Peyer's patches:an ultrastructural study of intestinal lymphoid follicles[J]. Gastroenterology,1974,66(2):189-203.
[74]WOLF J L, BYE W A. The membranous epithelial (M) cell and the mucosal immune system[J]. Annu Rev Med,1984,35:95-112.
[75]ERMAK T H, DOUGHERTY E P, BHAGAT H R, et al. Uptake and transport of copolymer biodegradable microspheres by rabbit Peyer's patch M cells[J]. Cell Tissue Res,1995,279(2):433-436.
[76]WOLF J L, RUBIN D H, FINBERG R, et al. Intestinal M cells:a pathway for entry of reovirus into the host[J]. Science,1981,212(4493):471-472.
[77]NIBERT M L, FURLONG D B, FIELDS B N. Mechanisms of viral pathogenesis. Distinct forms of reoviruses and their roles during replication in cells and host[J]. J Clin Invest,1991,88(3):727-734.
[78]WU Y, BOYSUN M J, CSENCSITS K L, et al. Gene transfer facilitated by a cellular targeting molecule, reovirus protein sigmal [J]. Gene Ther,2000,7(1):61-69.
[79]WU Y, WANG X, CSENCSITS K L, et al. M cell-targeted DNA vaccination[J]. Proc Natl Acad Sci U S A,2001,98(16):9318-9323.
[80]NOCHI T, YUKI Y, MATSUMURA A, et al. A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses[J]. J Exp Med, 2007,204(12):2789-2796.
[81]KIM S H, SEO K W, KIM J, et al. The M cell-targeting ligand promotes antigen delivery and induces antigen-specific immune responses in mucosal vaccination[J]. J Immunol,2010,185(10):5787-5795.
[82]LAPORTE J. The structure of foot-and-mouth disease virus protein[J]. J Gen Virol,1969,4(4):631-634.
[83]ROWLANDS D J, SANGAR D V, BROWN F. Relationship of the antigenic structure of foot-and-mouth disease virus to the process of infection [J]. J Gen Virol,1971,13(1):85-93.
[84]BACHRACH H L, MOORE D M, MCKERCHER P D, et al. Immune and antibody responses to an isolated capsid protein of foot-and-mouth disease virus[J]. J Immunol,1975,115(6):1636-1641.
[85]KUPPER H, KELLER W, KURZ C, et al. Cloning of cDNA of major antigen of foot and mouth disease virus and expression in E. coli[J]. Nature,1981,289(5798):555-559.
[86]KLEID D G, YANSURA D, SMALL B, et al. Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swine[J]. Science,1981,214(4525):1125-1129.
[87]BALAMURUGAN V, RENJI R, VENKATESH G, et al. Protective immune response against foot-and-mouth disease virus challenge in guinea pigs vaccinated with recombinant PI polyprotein expressed in Pichia pastoris[J]. Arch Virol,2005,150(5):967-979.
[88]SHI X J, WANG B, ZHANG C, et al. Expressions of Bovine IFN-gamma and foot-and-mouth disease VPl antigen in P. pastoris and their effects on mouse immune response to FMD antigens[J]. Vaccine, 2006,24(1):82-89.
[89]GIAVEDONI L D, KAPLAN G, MARCOVECCHIO F, et al. Protection conferred by TrpE fusion proteins containing portions of the C-terminal region of capsid protein VPl of foot-and-mouth disease virus[J]. J Gen Virol,1991,72 (Pt4):967-971.
[90]ROWLANDS D J, SANGAR D V, BROWN F. Relationship of the antigenic structure of foot-and-mouth disease virus to the process of infection[J]. J Gen Virol,1971,13(1):85-93.
[91]ROOSIEN J, BELSHAM G J, RYAN M D, et al. Synthesis of foot-and-mouth disease virus capsid proteins in insect cells using baculovirus expression vectors[J]. J Gen Virol,1990,71 (Pt 8):1703-1711.
[92]CAO Y, LU Z, SUN J, et al. Synthesis of empty capsid-like particles of Asia I foot-and-mouth disease virus in insect cells and their immunogenicity in guinea pigs [J]. Vet Microbiol,2009,137(1-2):10-17.
[93]CAO Y, SUN P, FU Y, et al. Formation of virus-like particles from O-type foot-and-mouth disease virus in insect cells using codon-optimized synthetic genes[J]. Biotechnol Lett,2010,32(9):1223-1229.
[94]LEWIS S A, MORGAN D O, GRUBMAN M J. Expression, processing, and assembly of foot-and-mouth disease virus capsid structures in heterologous systems:induction of a neutralizing antibody response in guinea pigs[J]. J Virol,1991,65(12):6572-6580.
[95]LEE C D, YAN Y P, LIANG S M, et al. Production of FMDV virus-like particles by a SUMO fusion protein approach in Escherichia coli[J]. J Biomed Sci,2009,16:69.
[96]Doel T R. FMD vaccines[J]. Virus Res,2003,91(1):81-99.
[97]GRUBMAN M J. Development of novel strategies to control foot-and-mouth disease:marker vaccines and antivirals[J]. Biologicals,2005,33(4):227-234.
[98]PFAFF E, MUSSGAY M, BOHM H O, et al. Antibodies against a preselected peptide recognize and neutralize foot and mouth disease virus[J]. EMBO J,1982,1 (7):869-874.
[99]ACHARYA R, FRY E, STUART D, et al. The three-dimensional structure of foot-and-mouth disease virus at 2.9 A resolution[J]. Nature,1989,337(6209):709-716.
[100]BITTLE J L, HOUGHTEN R A, ALEXANDER H, et al. Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence[J]. Nature,1982,298(5869):30-33.
[101]DIMARCHI R, BROOKE G, GALE C, et al. Protection of cattle against foot-and-mouth disease by a synthetic peptide[J]. Science,1986,232(4750):639-641.
[102]BROWN F. New approaches to vaccination against foot-and-mouth disease[J]. Vaccine, 1992,10(14):1022-1026.
[103]TABOGA O, TAMI C, CARRILLO E, et al. A large-scale evaluation of peptide vaccines against foot-and-mouth disease:lack of solid protection in cattle and isolation of escape mutants[J]. J Virol, 1997,71(4):2606-2614.
[104]GARCIA-BRIONES M M, RUSSELL G C, OLIVER R A, et al. Association of bovine DRB3 alleles with immune response to FMDV peptides and protection against viral challenge[J]. Vaccine, 2000,19(9-10):1167-1171.
[105]FRANCIS M J, HASTINGS G Z, SYRED A D, et al. Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants[J]. Nature, 1987,330(6144):168-170.
[106]WANG C Y, CHANG T Y, WALFIELD A M, et al. Effective synthetic peptide vaccine for foot-and-mouth disease in swine[J]. Vaccine,2002,20(19-20):2603-2610.
[107]CUBILLOS C, DE LA TORRE B G, JAKAB A, et al. Enhanced mucosal immunoglobulin A response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide[J]. J Virol,2008,82(14):7223-7230.
[108]RIEDER E, BAXT B, LUBROTH J, et al. Vaccines prepared from chimeras of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies and protective immunity to multiple serotypes of FMDV[J]. J Virol,1994,68(11):7092-7098.
[109]MCKENNA T S, LUBROTH J, RIEDER E, et al. Receptor binding site-deleted foot-and-mouth disease (FMD) virus protects cattle from FMD[J]. J Virol,1995,69(9):5787-5790.
[110]PICCONE M E, RIEDER E, MASON P W, et al. The foot-and-mouth disease virus leader proteinase gene is not required for viral replication[J]. J Virol,1995,69(9):5376-5382.
[111]CHINSANGARAM J, MASON P W, GRUBMAN M J. Protection of swine by live and inactivated vaccines prepared from a leader proteinase-deficient serotype A12 foot-and-mouth disease virus[J]. Vaccine,1998,16(16):1516-1522.
[112]MASON P W, PICCONE M E, MCKENNA T S, et al. Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate[J]. Virology,1997,227(1):96-102.
[113]FOWLER V L, PATON D J, RIEDER E, et al. Chimeric foot-and-mouth disease viruses:evaluation of their efficacy as potential marker vaccines in cattle[J]. Vaccine,2008,26(16):1982-1989.
[114]LI S, GAO M, ZHANG R, et al. A mutant of infectious Asia 1 serotype foot-and-mouth disease virus with the deletion of 10-amino-acid in the 3A protein[J]. Virus Genes,2010,41(3):406-413.
[115]LI S, GAO M, ZHANG R, et al. A mutant of Asia 1 serotype of Foot-and-mouth disease virus with the deletion of an important antigenic epitope in the 3A protein[J]. Can J Microbiol,2011,57(3):169-176.
[116]HU Y, JIN H, DU X, et al. Effects of chronic heat stress on immune responses of the foot-and-mouth disease DNA vaccination[J]. DNA Cell Biol,2007,26(8):619-626.
[117]WONG H T, CHENG S C, CHAN E W, et al. Plasmids encoding foot-and-mouth disease virus VP1 epitopes elicited immune responses in mice and swine and protected swine against viral infection[J]. Virology,2000,278(1):27-35.
[118]BENVENISTI L, ROGEL A, KUZNETZOVA L, et al. Gene gun-mediate DNA vaccination against foot-and-mouth disease virus[J]. Vaccine,2001,19(28-29):3885-3895.
[119]SU B, WANG J, WANG X, et al. The effects of IL-6 and TNF-alpha as molecular adjuvants on immune responses to FMDV and maturation of dendritic cells by DNA vaccination [J]. Vaccine, 2008,26(40):5111-5122.
[120]WANG X, ZHANG X, KANG Y, et al. Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus[J]. Vaccine,2008,26(40):5135-5144.
[121]SHI X J, WANG B, ZHANG C, et al. Expressions of Bovine IFN-gamma and foot-and-mouth disease VP1 antigen in P. pastoris and their effects on mouse immune response to FMD antigens[J]. Vaccine, 2006,24(1):82-89.
[122]USHA R, ROHLL J B, SPALL V E, et al. Expression of an animal virus antigenic site on the surface of a plant virus particle[J]. Virology,1993,197(1):366-374.
[123]WIGDOROVITZ A, PEREZ F D, ROBERTSON N, et al. Protection of mice against challenge with foot and mouth disease virus (FMDV) by immunization with foliar extracts from plants infected with recombinant tobacco mosaic virus expressing the FMDV structural protein VP1[J]. Virology, 1999,264(1):85-91.
[124]CARRILLO C, WIGDOROVITZ A, TRONO K, et al. Induction of a virus-specific antibody response to foot and mouth disease virus using the structural protein VP1 expressed in transgenic potato plants[J]. Viral Immunol,2001,14(1):49-57.
[125]CARRILLO C, WIGDOROVITZ A, OLIVEROS J C, et al. Protective immune response to foot-and-mouth disease virus with VP1 expressed in transgenic plants[J]. J Virol, 1998,72(2):1688-1690.
[126]HUANG Y, LIANG W, WANG Y, et al. Immunogenicity of the epitope of the foot-and-mouth disease virus fused with a hepatitis B core protein as expressed in transgenic tobacco[J]. Viral Immunol, 2005,18(4):668-677.
[127]PAN L, ZHANG Y G, WANG Y L, et al. [Protective immune response of guinea pigs against challenge with foot and mouth disease virus by immunization with foliar extracts from transgenic tomato plants expressing the FMDV structural protein VP1][J]. Wei Sheng Wu Xue Bao,2006,46(5):796-801.
[128]DUS S M, CARRILLO C, ARDILA F, et al. Development of transgenic alfalfa plants containing the foot and mouth disease virus structural polyprotein gene P1 and its utilization as an experimental immunogen[J]. Vaccine,2005,23(15):1838-1843.
[129]王炜.口蹄疫病毒P12A-3C基因在百脉根中的表达及其免疫豚鼠实验[D].兰州：中国农业科学院兰州兽医所.
[130]JUILLARD V, VILLEFROY P, GODFRIN D, et al. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector[J]. Eur J Immunol, 1995,25(12):3467-3473.
[131]FOOKS A R, JEEVARAJAH D, LEE J, et al. Oral or parenteral administration of replication-deficient adenoviruses expressing the measles virus haemagglutinin and fusion proteins:protective immune responses in rodents[J]. J Gen Virol,1998,79 (Pt 5):1027-1031.
[132]SANZ-PARRA A, JIMENEZ-CLAVERO M A, GARCIA-BRIONES M M, et al. Recombinant viruses expressing the foot-and-mouth disease virus capsid precursor polypeptide (P1) induce cellular but not humoral antiviral immunity and partial protection in pigs[J]. Virology,1999,259(1):129-134.
[133]MAYR G A, CHINSANGARAM J, GRUBMAN M J. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate[J]. Virology,1999,263(2):496-506.
[134]金宁一,张洪勇,尹革芬,等.共表达口蹄疫病毒衣壳蛋白前体P1-2A基因和蛋白酶3C基因重组鸡痘病毒的构建及其免疫原性[J].科学通报,2004(06).
[135]MA M, JIN N, SHEN G, et al. Immune responses of swine inoculated with a recombinant fowlpox virus co-expressing P12A and 3C of FMDV and swine IL-18[J]. Vet Immunol Immunopathol, 2008,121(1-2):1-7.
[136]刘明秋,牛晓峰,严维耀.以减毒猪霍乱沙门菌为载体的抗O型口蹄疫病毒重组活菌苗在家兔体内免疫应答的初步研究[J].Journal of Fudan University (Natural Science),2005,44(4):484-489.
[137]LI Y G, TIAN F L, GAO F S, et al. Immune responses generated by Lactobacillus as a carrier in DNA immunization against foot-and-mouth disease virus[J]. Vaccine,2007,25(5):902-911.
[138]李云岗,田夫林,王会波.以乳酸杆菌为载体的口蹄疫病毒VP1基因DNA疫苗猪体免疫试验 [J].中国兽医科学,2006,36(8)：601-605.
[139]MORGAN D O, MOORE D M. Protection of cattle and swine against foot-and-mouth disease, using biosynthetic peptide vaccines[J]. Am J Vet Res,1990,51(1):40-45.
[140]ZHANG H Y, SUN S H, GUO Y J, et al. Immune response in mice inoculated with plasmid DNAs containing multiple-epitopes of foot-and-mouth disease virus[J]. Vaccine,2003,21(32):4704-4707.
[141]WANG F, HE X W, JIANG L, et al. Enhanced immunogenicity of microencapsulated multiepitope DNA vaccine encoding T and B cell epitopes of foot-and-mouth disease virus in mice[J]. Vaccine, 2006,24(12):2017-2026.
[142]HU B, LI C, LU H, et al. Immune responses to the oral administration of recombinant Bacillus subtilis expressing multi-epitopes of foot-and-mouth disease virus and a cholera toxin B subunit[J]. J Virol Methods,201 1,171(1):272-279.
[143]FRANCIS M J, HASTINGS G Z, BROWN A L, et al. Immunological properties of hepatitis B core antigen fusion proteins[J]. Proc Natl Acad Sci U S A, 1990,87(7):2545-2549.
[144]PUMPENS P, GRENS E. HBV core particles as a carrier for B cell/T cell epitopes[J]. Intervirology, 2001,44(2-3):98-114.
[145]MILICH D R, PETERSON D L, SCHODEL F, et al. Preferential recognition of hepatitis B nucleocapsid antigens by Thl or Th2 cells is epitope and major histocompatibility complex dependent[J]. J Virol,1995,69(5):2776-2785.
[146]FEHR T, SKRASTINA D, PUMPENS P, et al. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles[J]. Proc Natl Acad Sci U S A, 1998,95(16):9477-9481.
[147]MILICH D R, CHEN M, SCHODEL F, et al. Role of B cells in antigen presentation of the hepatitis B core[J]. Proc Natl Acad Sci U S A, 1997,94(26):14648-14653.
[148]LAZDINA U, CAO T, STEINBERGS J, et al. Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B cells[J]. J Virol, 2001,75(14):6367-6374.
[149]PUMPENS P, GRENS E. Hepatitis B core particles as a universal display model:a structure-function basis for development[J]. FEBS Lett,1999,442(1):1-6.
[150]DE FILETTE M, MIN J W, BIRKETT A, et al. Universal influenza A vaccine:optimization of M2-based constructs[J]. Virology,2005,337(1):149-161.
[151]PUMPENS P, GRENS E. HBV core particles as a carrier for B cell/T cell epitopes[J]. Intervirology, 2001,44(2-3):98-114.
[152]YIN Y, ZHANG J, DONG D, et al. Chimeric hepatitis B virus core particles carrying an epitope of anthrax protective antigen induce protective immunity against Bacillus anthracis[J]. Vaccine, 2008,26(46):5814-5821.
[153]WANG Y S, OUYANG W, LIU X J, et al. Virus-like particles of hepatitis B virus core protein containing five mimotopes of infectious bursal disease virus (IBDV) protect chickens against IBDV[J]. Vaccine,2012,30(12):2125-2130.
[154]CHAMBERS M A, DOUG AN G, NEWMAN J, et al. Chimeric hepatitis B virus core particles as probes for studying peptide-integrin interactions[J]. J Virol,1996,70(6):4045-4052.
[155]ZHANG Y L, GUO Y J, WANG K. Y, et al. Enhanced immunogenicity of modified hepatitis B virus core particle fused with multiepitopes of foot-and-mouth disease virus[J]. Scand J Immunol, 2007,65(4):320-328.
[156]REN F, XU Y, MAO L, et al. Heat shock protein 110 improves the antitumor effects of the cytotoxic T lymphocyte epitope E7(49-57) in mice[J]. Cancer Biol Ther,2010,9(2):134-141.
[157]肖志军,张改平,杨汉春.传染性法氏囊病病毒VP2蛋白B细胞抗原表位免疫小鼠试验[J].华北农学报,2010,25(2)：233-235.
[158]宋幸辉,王睿,王选年.染性法氏囊病毒VP2蛋白抗原表位多肽P22的免疫原性及生物学功能鉴定[J].畜牧兽医学报,2011,42(5)：692-697.
[159]朱彦彩,王选年,银梅.His6免疫原的制备及免疫小鼠抗体效价检测[J].河南农业科学,2007,12：116-118.
[160]SHAO J J, WONG C K, LIN T, et al. Promising multiple-epitope recombinant vaccine against foot-and-mouth disease virus type O in swine[J]. Clin Vaccine Immunol,2011,18(1):143-149.
[161]DU Y, LI Y, HE H, et al. Enhanced immunogenicity of multiple-epitopes of foot-and-mouth disease virus fused with porcine interferon alpha in mice and protective efficacy in guinea pigs and swine[J]. J Virol Methods,2008,149(1):144-152.
[162]LI J, LI K N, GAO J, et al. Heat shock protein 70 fused to or complexed with hantavirus nucleocapsid protein significantly enhances specific humoral and cellular immune responses in C57BL/6 mice[J]. Vaccine,2008,26(25):3175-3187.
[163]CHAN E W, WONG H T, CHENG S C, et al. An immunoglobulin G based chimeric protein induced foot-and-mouth disease specific immune response in swine[J]. Vaccine,2000,19(4-5):538-546.
[164]YI J Z, LIU M Q, ZHU C Z, et al. Recombinant bivalent vaccine against foot-and-mouth disease virus serotype O/A infection in guinea pig[J]. Acta Biochim Biophys Sin (Shanghai),2004,36(9):589-596.
[165]ZENG W, HORROCKS K J, ROBEVSKA G, et al. A modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building[J]. J Biol Chem,2011,286(15):12944-12951.
[166]COBB A, ROBERTS L K, PALUCKA A K, et al. Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine[J]. J Immunol Methods,201 1,365(1-2):27-37.
[167]SOLANO-PARADA J, GONZALEZ-GONZALEZ G, TORRO L M, et al. Effectiveness of intranasal vaccination against Angiostrongylus costaricensis using a serine/threonine phosphatase 2 A synthetic peptide and recombinant antigens[J]. Vaccine,2010,28(32):5185-5196.
[168]PAHAR B, CANTU M A, ZHAO W, et al. Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV[J]. Vaccine, 2006,24(47-48):6839-6849.
[169]SONG H, WANG Z, ZHENG D, et al. A novel mucosal vaccine against foot-and-mouth disease virus induces protection in mice and swine[J]. Biotechnol Lett,2005,27(21):1669-1674.
[170]WANG G, PAN L, ZHANG Y, et al. Intranasal delivery of cationic PLGA nano/microparticles-loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge[J]. PLoS One,2011,6(11):e27605.
[171]王潇,王志钢,杜瑞平.白细胞介素-10分子佐剂增强口蹄疫DNA疫苗黏膜免疫效果研究[J].中国农业科学,2011(14)：3045-3052.
[172]CHALLA S, SZCZEPANEK S M, ROOD D, et al. Bacterial Toxin Fusion Proteins Elicit Mucosal Immunity against a Foot-and-Mouth Disease Virus Antigen When Administered Intranasally to Guinea Pigs[J]. Adv Virol,2011,2011:713769.
[173]MORGAN D O, MOORE D M. Protection of cattle and swine against foot-and-mouth disease, using biosynthetic peptide vaccines[J]. Am J Vet Res,1990,51(1):40-45.
[174]BROWN F, BENKIRANE N, LIMAL D, et al. Delineation of a neutralizing subregion within the immunodominant epitope (GH loop) of foot-and-mouth disease virus VP1 which does not contain the RGD motif[J]. Vaccine,1999,18(1-2):50-56.
[175]CARR B V, LEFEVRE E A, WINDSOR M A, et al. CD4+ T-cell responses to foot-and-mouth disease virus in vaccinated cattle[J]. J Gen Virol,2013,94(Pt 1):97-107.
[176]COLLEN T, DIMARCHI R, DOEL T R. A T cell epitope in VP1 of foot-and-mouth disease virus is immunodominant for vaccinated cattle[J]. J Immunol,1991,146(2):749-755.
[177]BLANCO E, GARCIA-BRIONES M, SANZ-PARRA A, et al. Identification of T-cell epitopes in nonstructural proteins of foot-and-mouth disease virus[J]. J Virol,2001,75(7):3164-3174.
[178]CIANGA P, MEDESAN C, RICHARDSON J A, et al. Identification and function of neonatal Fc receptor in mammary gland of lactating mice[J]. Eur J Immunol,1999,29(8):2515-2523.
[179]郭德军,柳增善.黑曲霉GA Ⅰ基因的克隆及在P.pastoris中的分泌表达[J].黑龙江八一农垦大学学报,2005,17(4)：69-72.
[180]FABER K N, HARDER W, AB G, et al. Review:methylotrophic yeasts as factories for the production of foreign proteins[J]. Yeast,1995,11(14):1331-1344.
[181]ZHANG Y, LIU X, WANG M. Cloning, expression, and characterization of two novel cuticle-degrading serine proteases from the entomopathogenic fungus Cordyceps sinensis[J]. Res Microbiol,2008,159(6):462-469.
[182]DOEL T R, COLLEN T. Qualitative assessment of 146 S particles of foot-and-mouth disease virus in preparations destined for vaccines[J]. J Biol Stand,1982,10(2):69-81.
[183]WANG J L, LIU M Q, HAN J, et al. A peptide of foot-and-mouth disease virus serotype Asial generating a neutralizing antibody response, and an immunostimulatory peptide[J]. Vet Microbiol, 2007,125(3-4):224-231.
[184]KLEID D G, YANSURA D, Small B, et al. Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swine[J]. Science,1981,214(4525):1125-1129.
[185]MILICH D R, PETERSON D L, SCHODEL F, et al. Preferential recognition of hepatitis B nucleocapsid antigens by Thl or Th2 cells is epitope and major histocompatibility complex dependent[J]. J Virol,1995,69(5):2776-2785.
[186]FEHR T, SKRASTINA D, PUMPENS P, et al. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles[J]. Proc Nat] Acad Sci U S A, 1998,95(16):9477-9481.
[187]MILICH D R, CHEN M, SCHODEL F, et al. Role of B cells in antigen presentation of the hepatitis B core[J]. Proc Natl Acad Sci U S A, 1997,94(26):14648-14653.
[188]PRATO M M, FORSYTH M A, BELSHAM G J, et al. Localization of foot-and-mouth disease virus RNA by in situ hybridization within bovine tissues[J]. Virus Res,1999,62(1):67-76.
[189]HOLMGREN J, CZERKINSKY C, ERIKSSON K, et al. Mucosal immunisation and adjuvants:a brief overview of recent advances and challenges[J]. Vaccine,2003,21 Suppl 2:S89-S95.
[190]XU W, SHEN Y, JIANG Z, et al. Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection[J]. Vaccine,2004,22(27-28):3603-3612.
[191]KWEON M N. Sublingual mucosa:A new vaccination route for systemic and mucosal immunity[J]. Cytokine,2011,54(1):1-5.
[192]GREENBAUM E, ENGELHARD D, LEVY R, et al. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine[J]. Vaccine,2004,22(20):2566-2577.
[193]FISCHER D, ROOD D, BARRETTE R W, et al. Intranasal immunization of guinea pigs with an immunodominant foot-and-mouth disease virus peptide conjugate induces mucosal and humoral antibodies and protection against challenge[J]. J Virol,2003,77(13):7486-7491.
[194]BRANDTZAEG P. Induction of secretory immunity and memory at mucosal surfaces[J]. Vaccine, 2007,25(30):5467-5484.
[195]ERIKSSON K, HOLMGREN J. Recent advances in mucosal vaccines and adjuvants[J]. Curr Opin Immunol,2002,14(5):666-672.
[196]郝生宏,杨荣芳.黏膜免疫[J].营养与疾病,2004(4)：42-44.
[197]SHAH U, DICKINSON B L, BLUMBERG R S, et al. Distribution of the IgG Fc receptor, FcRn, in the human fetal intestine[J]. Pediatr Res,2003,53(2):295-301.
[198]ZHU X, MENG G, DICKINSON B L, et al. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells[J]. J Immunol, 2001,166(5):3266-3276.
[199]STIRLING C M, CHARLESTON B, TAKAMATSU H, et al. Characterization of the porcine neonatal Fc receptor--potential use for trans-epithelial protein delivery[J]. Immunology,2005,114(4):542-553.
[200]MAYER B, KIS Z, KAJAN G, et al. The neonatal Fc receptor (FcRn) is expressed in the bovine lung[J]. Vet Immunol Immunopathol,2004,98(1-2):85-89.
[201]OBER R J, RADU C G, GHETIE V, et al. Differences in promiscuity for anlibody-FcRn interactions across species:implications for therapeutic antibodies[J]. Int Immunol,2001,13(12):1551-1559.
[202]NEUTRA M R, KOZLOWSKI P A. Mucosal vaccines:the promise and the challenge[J]. Nat Rev Immunol,2006,6(2):148-158.
[203]HOLMGREN J, CZERKINSKY C. Mucosal immunity and vaccines[J]. Nat Med,2005,11(4 Suppl):S45-S53.
[204]GALLICHAN W S, ROSENTHAL K L. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization[J]. J Infect Dis,1998,177(5):1155-1161.
[205]MESTECKY J, RUSSELL M W, ELSON C O. Perspectives on mucosal vaccines:is mucosal tolerance a barrier?[J]. J Immunol,2007,179(9):5633-5638.
[2]谢庆阁.口蹄疫[M].北京：中国农业出版社,2004.
[3]毕应佐.口蹄疫[M].广州：广东科技出版社,2005.
[4]MORT M, CONVERY I, BAXTER J, et al. Psychosocial effects of the 2001 UK foot and mouth disease epidemic in a rural population:qualitative diary based study[J]. BMJ,2005,331(7527):1234.
[5]KNOWLES N J, SAMUEL A R. Molecular epidemiology of foot-and-mouth disease virus[J]. Virus Res,2003,91(1):65-80.
[6]KITCHING R P. Global epidemiology and prospects for control of foot-and-mouth disease[J]. Curr Top Microbiol Immunol,2005,288:133-148.
[7]CARROLL A R, Rowlands D J, Clarke B E. The complete nucleotide sequence of the RNA coding for the primary translation product of foot and mouth disease virus[J]. Nucleic Acids Res, 1984,12(5):2461-2472.
[8]BELSHAM G J. Distinctive features of foot-and-mouth disease virus, a member of the picornavirus family; aspects of virus protein synthesis, protein processing and structure[J]. Prog Biophys Mol Biol, 1993,60(3):241-260.
[9]DOMINGO E, BARANOWSKI E, ESCARMIS C, et al. Foot-and-mouth disease virus[J]. Comp Immunol Microbiol Infect Dis,2002,25(5-6):297-308.
[10]PFAFF E, THIEL H J, BECK E, et al. Analysis of neutralizing epitopes on foot-and-mouth disease virus[J]. J Virol,1988,62(6):2033-2040.
[11]BUTCHAIAH G, MORGAN D O. Neutralization antigenic sites on type Asia-1 foot-and-mouth disease virus defined by monoclonal antibody-resistant variants[J]. Virus Res,1997,52(2):183-194.
[12]SANTINA GRAZIOLI F F E B. Mapping of neutralising sites on FMD virus type Asial and relationships with sites described in other serotypes[J]. Report of the Session of the Research Group of theStanding Committee of the European Commission of Footand Mouth Disease,2003,Appendix (44):277-287.
[13]GARABED R B, JOHNSON W O, THURMOND M C. Analytical epidemiology of genomic variation among Pan Asia strains of foot-and-mouth disease virus [J]. Transbound Emerg Dis, 2009,56(4):142-156.
[14]RANA S K, BAGCHI T. Partial sequence analysis of VP1 of Indian isolates of foot-and-mouth disease virus type Asia-1 [J]. Virus Genes,2008,37(1):60-68.
[15]BARNETT P V, OULDRIDGE E J, ROWLANDS D J, et al. Neutralizing epitopes of type O foot-and-mouth disease virus. I. Identification and characterization of three functionally independent, conformational sites[J]. J Gen Virol,1989,70 (Pt 6):1483-1491.
[16]CROWTHER J R, FARIAS S, CARPENTER W C, et al. Identification of a fifth neutralizable site on type O foot-and-mouth disease virus following characterization of single and quintuple monoclonal antibody escape mutants[J]. J Gen Virol,1993,74 (Pt 8):1547-1553.
[17]SAIZ J C, GONZALEZ M J, BORCA M V, et al. Identification of neutralizing antigenic sites on VP1 and VP2 of type A5 foot-and-mouth disease virus, defined by neutralization-resistant variants[J]. J Virol, 1991,65(5):2518-2524.
[18]THOMAS A A, WOORTMEIJER R J, PUIJK W, et al. Antigenic sites on foot-and-mouth disease virus type A10[J]. J Virol,1988,62(8):2782-2789.
[19]COLLEN T, DIMARCHI R, DOEL T R. A T cell epitope in VP1 of foot-and-mouth disease virus is immunodominant for vaccinated cattle[J]. J Immunol,1991,146(2):749-755.
[20]ZAMORANO P, WIGDOROVITZ A, CHAHER M T, et al. Recognition of B and T cell epitopes by cattle immunized with a synthetic peptide containing the major immunogenic site of VP1 FMDV 01 Campos[J]. Virology,1994,201(2):383-387.
[21]VAN LIEROP M J, WAGENAAR J P, VAN NOORT J M, ET AL. Sequences derived from the highly antigenic VP1 region 140 to 160 of foot-and-mouth disease virus do not prime for a bovine T-cell response against intact virus[J]. J Virol,1995,69(7):4511-4514.
[22]杨志军.含T细胞表位和B细胞表位的抗0型FMDV基因工程疫苗诱导豚鼠产生免疫反应[J].2000.
[23]FOSTER M, COOK A, CEDILLO L, et al. Serological and cellular immune responses to non-structural proteins in animals infected with FMDV[J]. Vet Q,1998,20 Suppl 2:S28-S30.
[24]BLANCO E, GARCIA-BRIONES M, SANZ-PARRA A, et al. Identification of T-cell epitopes in nonstructural proteins of foot-and-mouth disease virus[J]. J Virol,2001,75(7):3164-3174.
[25]GERNER W, DENYER M S, TAKAMATSU H H, et al. Identification of novel foot-and-mouth disease virus specific T-cell epitopes in c/c and d/d haplotype miniature swine[J]. Virus Res, 2006,121(2):223-228.
[26]SUTMOLLER P, MCVICAR J W, COTTRAL G E. The epizootiological importance of foot-and-mouth disease carriers. I. Experimentally produced foot-and-mouth disease carriers in susceptible and immune cattle[J]. Arch Gesamte Virusforsch,1968,23(3):227-235.
[27]VALARCHER J F, KNOWLES N J, FERRIS N P, et al. Recent spread of FMD virus serotype Asia 1[J]. Vet Rec,2005,157(1):30.
[28]王世若,王兴龙.现代动物免疫学[M].吉林科学技术出版社,1999.
[29]阴天榜,刘兴友.家禽免疫学[M].北京：中国农业科技出版社,1999.
[30]罗红林,黄维义.动物黏膜免疫及其细胞因子[J].吉林畜牧兽医,2004,5：19-21.
[31]KUNISAWA J, FUKUYAMA S, KIYONO H. Mucosa-associated lymphoid tissues in the aerodigestive tract:their shared and divergent traits and their importance to the orchestration of the mucosal immune system[J]. Curr Mol Med,2005,5(6):557-572.
[32]马玉龙,许梓荣.肠道黏膜免疫研究进展[J].中国畜牧杂志,2004,31.
[33]NEUTRA M R. Current concepts in mucosal immunity. V Role of M cells in transepithelial transport of antigens and pathogens to the mucosal immune system[J]. Am J Physiol,1998,274(5 Pt 1):G785-G791.
[34JRODRIGUEZ A, ROTTENBERG M, TJARNLUND A, et al. Immunoglobulin A and CD8 T-cell mucosal immune defenses protect against intranasal infection with Chlamydia pneumoniae[J]. Scand J Immunol,2006,63(3):177-183.
[35]YASUDA Y, ISAKA M, TANIGUCHI T, et al. Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies[J]. Vaccine, 2003,21 (21-22):2954-2963.
[36]FREYTAG L C, CLEMENTS J D. Bacterial toxins as mucosal adjuvants[J]. Curr Top Microbiol Immunol,1999,236:215-236.
[37]BAGLEY K C, ABDELWAHAB S F, TUSKAN R G, et al. Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway[J]. Infect Immun,2002,70(10):5533-5539.
[38]SHREEDHAR V K, KELSALL B L, NEUTRA M R. Cholera toxin induces migration of dendritic cells from the subepithelial dome region to T-and B-cell areas of Peyer's patches[J]. Infect Immun, 2003,71(1):504-509.
[39]张小飞,杨倩.黏膜免疫佐剂的研究进展[J].免疫学杂志,2004,20(3)：62-65.
[40]BOYAKA P N, MARINARO M, JACKSON R J, et al. IL-12 is an effective adjuvant for induction of mucosal immunity[J]. J Immunol,1999,162(1):122-128.
[41]HUBER V C, ARULANANDAM B P, ARNABOLDI P M, et al. Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity[J]. Int Immunopharmacol,2003,3(6):801-809.
[42]PROIETTI E, BRACCI L, PUZELLI S, et al. Type IIFN as a natural adjuvant for a protective immune response:lessons from the influenza vaccine model[J]. J Immunol,2002,169(1):375-383.
[43]PLAYFAIR J H, DE SOUZA J B. Recombinant gamma interferon is a potent adjuvant for a malaria vaccine in mice[J]. Clin Exp Immunol,1987,67(1):5-10.
[44]BRADNEY C P, SEMPOWSKI G D, LIAO H X, et al. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization [J]. J Virol,2002,76(2):517-524.
[45]TELONI R, VON HUNOLSTEIN C, MARIOTTI S, et al. Antibody classes & subclasses induced by mucosal immunization of mice with Streptococcus pyogenes M6 protein & oligodeoxynucleotides containing CpG motifs[J]. Indian J Med Res,2004,119 Suppl:126-130.
[46]GALLICHAN W S, WOOLSTENCROFT R N, GUARASCI T, et al. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract[J], J Immunol,2001,166(5):3451-3457.
[47]STEINMAN R M, COHN Z A. The interaction of soluble horseradish peroxidase with mouse peritoneal macrophages in vitro[J]. J Cell Biol,1972,55(1):186-204.
[48]STEINMAN R M, COHN Z A. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution[J]. J Exp Med,1973,137(5):1142-1162.
[49]NUSSENZWEIG M C, STEINMAN R M, GUTCHINOV B, et al. Dendritic cells are accessory cells for the development of anti-trinitrophenyl cytotoxic T lymphocytes[J]. J Exp Med, 1980,152(4):1070-1084.
[50]MARASKOVSKY E, BRASEL K, TEEPE M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice:multiple dendritic cell subpopulations identified[J]. J Exp Med,1996,184(5):1953-1962.
[51]LYMAN S D, JAMES L, VANDEN B T, et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor:a proliferative factor for primitive hematopoietic cells[J]. Cell,1993,75(6):1157-1167.
[52]HUNG C F, HSU K F, CHENG W F, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand[J]. Cancer Res,2001,61(3):1080-1088.
[53]MOORE A C, KONG W P, CHAKRABARTI B K, et al. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice[J]. J Virol, 2002,76(1):243-250.
[54]KATAOKA K, MCGHEE J R, KOBAYASHI R, et al. Nasal Flt3 ligand cDNA elicits CD1 lc+CD8+ dendritic cells for enhanced mucosal immunity[J]. J Immunol,2004,172(6):3612-3619.
[55]SEKINE S, KATAOKA K, FUKUYAMA Y, et al. A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration[J]. J Immunol,2008,180(12):8126-8134.
[56]GHETIE V, WARD E S. Multiple roles for the major histocompatibility complex class I-related receptor FcRn[J]. Annu Rev Immunol,2000,18:739-766.
[57]HE W, LADINSKY M S, HUEY-TUBMAN K E, et al. FcRn-mediated antibody transport across epithelial cells revealed by electron tomography[J]. Nature,2008,455(7212):542-546.
[58]DICKINSON B L, BADIZADEGAN K, WU Z, et al. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line[J]. J Clin Invest,1999,104(7):903-911.
[59]ROOPENIAN D C, AKILESH S. FcRn:the neonatal Fc receptor comes of age[J]. Nat Rev Immunol, 2007,7(9):715-725.
[60]BAKER K, QIAO S W, KUO T, et al. Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn[J]. Semin Immunopathol,2009,31(2):223-236.
[61]YOSHIDA M, KOBAYASHI K, KUO T T, et al. Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria[J]. J Clin Invest,2006,116(8):2142-2151.
[62]SIMISTER N E, MOSTOV K E. An Fc receptor structurally related to MHC class I antigens[J]. Nature, 1989,337(6203):184-187.
[63]ROOPENIAN D C, AKILESH S. FcRn:the neonatal Fc receptor comes of age[J]. Nat Rev Immunol, 2007,7(9):715-725.
[64]BAKER K, QIAO S W, KUO T, et al. Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn[J]. Semin Immunopathol,2009,31(2):223-236.
[65]CHAUDHURY C, MEHNAZ S, ROBINSON J M, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan[J]. J Exp Med, 2003,197(3):315-322.
[66]DUMONT J A, BITONTI A J, CLARK D, et al. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway[J]. J Aerosol Med, 2005,18(3):294-303.
[67]STIRLING C M, CHARLESTON B, TAKAMATSU H, et al. Characterization of the porcine neonatal Fc receptor--potential use for trans-epithelial protein delivery[J]. Immunology,2005,114(4):542-553.
[68]YE L, ZENG R, BAI Y, et al. Efficient mucosal vaccination mediated by the neonatal Fc receptor[J]. Nat Biotechnol,2011,29(2):158-163.
[69]BOCKMAN D E, COOPER M D. Pinocytosis by epithelium associated with lymphoid follicles in the bursa of Fabricius, appendix, and Peyer's patches. An electron microscopic study[J]. Am J Anat, 1973,136(4):455-477.
[70]FARSTAD I N, HALSTENSEN T S, FAUSA O, et al. Heterogeneity of M-cell-associated B and T cells in human Peyer's patches[J]. Immunology,1994,83(3):457-464.
[71]GEBERT A, ROTHKOTTER H J, PABST R. M cells in Peyer's patches of the intestine[J]. Int Rev Cytol,1996,167:91-159.
[72]NEUTRA M R, FREY A, KRAEHENBUHL J P. Epithelial M cells:gateways for mucosal infection and immunization[J]. Cell,1996,86(3):345-348.
[73]OWEN R L, JONES A L. Epithelial cell specialization within human Peyer's patches:an ultrastructural study of intestinal lymphoid follicles[J]. Gastroenterology,1974,66(2):189-203.
[74]WOLF J L, BYE W A. The membranous epithelial (M) cell and the mucosal immune system[J]. Annu Rev Med,1984,35:95-112.
[75]ERMAK T H, DOUGHERTY E P, BHAGAT H R, et al. Uptake and transport of copolymer biodegradable microspheres by rabbit Peyer's patch M cells[J]. Cell Tissue Res,1995,279(2):433-436.
[76]WOLF J L, RUBIN D H, FINBERG R, et al. Intestinal M cells:a pathway for entry of reovirus into the host[J]. Science,1981,212(4493):471-472.
[77]NIBERT M L, FURLONG D B, FIELDS B N. Mechanisms of viral pathogenesis. Distinct forms of reoviruses and their roles during replication in cells and host[J]. J Clin Invest,1991,88(3):727-734.
[78]WU Y, BOYSUN M J, CSENCSITS K L, et al. Gene transfer facilitated by a cellular targeting molecule, reovirus protein sigmal [J]. Gene Ther,2000,7(1):61-69.
[79]WU Y, WANG X, CSENCSITS K L, et al. M cell-targeted DNA vaccination[J]. Proc Natl Acad Sci U S A,2001,98(16):9318-9323.
[80]NOCHI T, YUKI Y, MATSUMURA A, et al. A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses[J]. J Exp Med, 2007,204(12):2789-2796.
[81]KIM S H, SEO K W, KIM J, et al. The M cell-targeting ligand promotes antigen delivery and induces antigen-specific immune responses in mucosal vaccination[J]. J Immunol,2010,185(10):5787-5795.
[82]LAPORTE J. The structure of foot-and-mouth disease virus protein[J]. J Gen Virol,1969,4(4):631-634.
[83]ROWLANDS D J, SANGAR D V, BROWN F. Relationship of the antigenic structure of foot-and-mouth disease virus to the process of infection [J]. J Gen Virol,1971,13(1):85-93.
[84]BACHRACH H L, MOORE D M, MCKERCHER P D, et al. Immune and antibody responses to an isolated capsid protein of foot-and-mouth disease virus[J]. J Immunol,1975,115(6):1636-1641.
[85]KUPPER H, KELLER W, KURZ C, et al. Cloning of cDNA of major antigen of foot and mouth disease virus and expression in E. coli[J]. Nature,1981,289(5798):555-559.
[86]KLEID D G, YANSURA D, SMALL B, et al. Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swine[J]. Science,1981,214(4525):1125-1129.
[87]BALAMURUGAN V, RENJI R, VENKATESH G, et al. Protective immune response against foot-and-mouth disease virus challenge in guinea pigs vaccinated with recombinant PI polyprotein expressed in Pichia pastoris[J]. Arch Virol,2005,150(5):967-979.
[88]SHI X J, WANG B, ZHANG C, et al. Expressions of Bovine IFN-gamma and foot-and-mouth disease VPl antigen in P. pastoris and their effects on mouse immune response to FMD antigens[J]. Vaccine, 2006,24(1):82-89.
[89]GIAVEDONI L D, KAPLAN G, MARCOVECCHIO F, et al. Protection conferred by TrpE fusion proteins containing portions of the C-terminal region of capsid protein VPl of foot-and-mouth disease virus[J]. J Gen Virol,1991,72 (Pt4):967-971.
[90]ROWLANDS D J, SANGAR D V, BROWN F. Relationship of the antigenic structure of foot-and-mouth disease virus to the process of infection[J]. J Gen Virol,1971,13(1):85-93.
[91]ROOSIEN J, BELSHAM G J, RYAN M D, et al. Synthesis of foot-and-mouth disease virus capsid proteins in insect cells using baculovirus expression vectors[J]. J Gen Virol,1990,71 (Pt 8):1703-1711.
[92]CAO Y, LU Z, SUN J, et al. Synthesis of empty capsid-like particles of Asia I foot-and-mouth disease virus in insect cells and their immunogenicity in guinea pigs [J]. Vet Microbiol,2009,137(1-2):10-17.
[93]CAO Y, SUN P, FU Y, et al. Formation of virus-like particles from O-type foot-and-mouth disease virus in insect cells using codon-optimized synthetic genes[J]. Biotechnol Lett,2010,32(9):1223-1229.
[94]LEWIS S A, MORGAN D O, GRUBMAN M J. Expression, processing, and assembly of foot-and-mouth disease virus capsid structures in heterologous systems:induction of a neutralizing antibody response in guinea pigs[J]. J Virol,1991,65(12):6572-6580.
[95]LEE C D, YAN Y P, LIANG S M, et al. Production of FMDV virus-like particles by a SUMO fusion protein approach in Escherichia coli[J]. J Biomed Sci,2009,16:69.
[96]Doel T R. FMD vaccines[J]. Virus Res,2003,91(1):81-99.
[97]GRUBMAN M J. Development of novel strategies to control foot-and-mouth disease:marker vaccines and antivirals[J]. Biologicals,2005,33(4):227-234.
[98]PFAFF E, MUSSGAY M, BOHM H O, et al. Antibodies against a preselected peptide recognize and neutralize foot and mouth disease virus[J]. EMBO J,1982,1 (7):869-874.
[99]ACHARYA R, FRY E, STUART D, et al. The three-dimensional structure of foot-and-mouth disease virus at 2.9 A resolution[J]. Nature,1989,337(6209):709-716.
[100]BITTLE J L, HOUGHTEN R A, ALEXANDER H, et al. Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence[J]. Nature,1982,298(5869):30-33.
[101]DIMARCHI R, BROOKE G, GALE C, et al. Protection of cattle against foot-and-mouth disease by a synthetic peptide[J]. Science,1986,232(4750):639-641.
[102]BROWN F. New approaches to vaccination against foot-and-mouth disease[J]. Vaccine, 1992,10(14):1022-1026.
[103]TABOGA O, TAMI C, CARRILLO E, et al. A large-scale evaluation of peptide vaccines against foot-and-mouth disease:lack of solid protection in cattle and isolation of escape mutants[J]. J Virol, 1997,71(4):2606-2614.
[104]GARCIA-BRIONES M M, RUSSELL G C, OLIVER R A, et al. Association of bovine DRB3 alleles with immune response to FMDV peptides and protection against viral challenge[J]. Vaccine, 2000,19(9-10):1167-1171.
[105]FRANCIS M J, HASTINGS G Z, SYRED A D, et al. Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants[J]. Nature, 1987,330(6144):168-170.
[106]WANG C Y, CHANG T Y, WALFIELD A M, et al. Effective synthetic peptide vaccine for foot-and-mouth disease in swine[J]. Vaccine,2002,20(19-20):2603-2610.
[107]CUBILLOS C, DE LA TORRE B G, JAKAB A, et al. Enhanced mucosal immunoglobulin A response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide[J]. J Virol,2008,82(14):7223-7230.
[108]RIEDER E, BAXT B, LUBROTH J, et al. Vaccines prepared from chimeras of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies and protective immunity to multiple serotypes of FMDV[J]. J Virol,1994,68(11):7092-7098.
[109]MCKENNA T S, LUBROTH J, RIEDER E, et al. Receptor binding site-deleted foot-and-mouth disease (FMD) virus protects cattle from FMD[J]. J Virol,1995,69(9):5787-5790.
[110]PICCONE M E, RIEDER E, MASON P W, et al. The foot-and-mouth disease virus leader proteinase gene is not required for viral replication[J]. J Virol,1995,69(9):5376-5382.
[111]CHINSANGARAM J, MASON P W, GRUBMAN M J. Protection of swine by live and inactivated vaccines prepared from a leader proteinase-deficient serotype A12 foot-and-mouth disease virus[J]. Vaccine,1998,16(16):1516-1522.
[112]MASON P W, PICCONE M E, MCKENNA T S, et al. Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate[J]. Virology,1997,227(1):96-102.
[113]FOWLER V L, PATON D J, RIEDER E, et al. Chimeric foot-and-mouth disease viruses:evaluation of their efficacy as potential marker vaccines in cattle[J]. Vaccine,2008,26(16):1982-1989.
[114]LI S, GAO M, ZHANG R, et al. A mutant of infectious Asia 1 serotype foot-and-mouth disease virus with the deletion of 10-amino-acid in the 3A protein[J]. Virus Genes,2010,41(3):406-413.
[115]LI S, GAO M, ZHANG R, et al. A mutant of Asia 1 serotype of Foot-and-mouth disease virus with the deletion of an important antigenic epitope in the 3A protein[J]. Can J Microbiol,2011,57(3):169-176.
[116]HU Y, JIN H, DU X, et al. Effects of chronic heat stress on immune responses of the foot-and-mouth disease DNA vaccination[J]. DNA Cell Biol,2007,26(8):619-626.
[117]WONG H T, CHENG S C, CHAN E W, et al. Plasmids encoding foot-and-mouth disease virus VP1 epitopes elicited immune responses in mice and swine and protected swine against viral infection[J]. Virology,2000,278(1):27-35.
[118]BENVENISTI L, ROGEL A, KUZNETZOVA L, et al. Gene gun-mediate DNA vaccination against foot-and-mouth disease virus[J]. Vaccine,2001,19(28-29):3885-3895.
[119]SU B, WANG J, WANG X, et al. The effects of IL-6 and TNF-alpha as molecular adjuvants on immune responses to FMDV and maturation of dendritic cells by DNA vaccination [J]. Vaccine, 2008,26(40):5111-5122.
[120]WANG X, ZHANG X, KANG Y, et al. Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus[J]. Vaccine,2008,26(40):5135-5144.
[121]SHI X J, WANG B, ZHANG C, et al. Expressions of Bovine IFN-gamma and foot-and-mouth disease VP1 antigen in P. pastoris and their effects on mouse immune response to FMD antigens[J]. Vaccine, 2006,24(1):82-89.
[122]USHA R, ROHLL J B, SPALL V E, et al. Expression of an animal virus antigenic site on the surface of a plant virus particle[J]. Virology,1993,197(1):366-374.
[123]WIGDOROVITZ A, PEREZ F D, ROBERTSON N, et al. Protection of mice against challenge with foot and mouth disease virus (FMDV) by immunization with foliar extracts from plants infected with recombinant tobacco mosaic virus expressing the FMDV structural protein VP1[J]. Virology, 1999,264(1):85-91.
[124]CARRILLO C, WIGDOROVITZ A, TRONO K, et al. Induction of a virus-specific antibody response to foot and mouth disease virus using the structural protein VP1 expressed in transgenic potato plants[J]. Viral Immunol,2001,14(1):49-57.
[125]CARRILLO C, WIGDOROVITZ A, OLIVEROS J C, et al. Protective immune response to foot-and-mouth disease virus with VP1 expressed in transgenic plants[J]. J Virol, 1998,72(2):1688-1690.
[126]HUANG Y, LIANG W, WANG Y, et al. Immunogenicity of the epitope of the foot-and-mouth disease virus fused with a hepatitis B core protein as expressed in transgenic tobacco[J]. Viral Immunol, 2005,18(4):668-677.
[127]PAN L, ZHANG Y G, WANG Y L, et al. [Protective immune response of guinea pigs against challenge with foot and mouth disease virus by immunization with foliar extracts from transgenic tomato plants expressing the FMDV structural protein VP1][J]. Wei Sheng Wu Xue Bao,2006,46(5):796-801.
[128]DUS S M, CARRILLO C, ARDILA F, et al. Development of transgenic alfalfa plants containing the foot and mouth disease virus structural polyprotein gene P1 and its utilization as an experimental immunogen[J]. Vaccine,2005,23(15):1838-1843.
[129]王炜.口蹄疫病毒P12A-3C基因在百脉根中的表达及其免疫豚鼠实验[D].兰州：中国农业科学院兰州兽医所.
[130]JUILLARD V, VILLEFROY P, GODFRIN D, et al. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector[J]. Eur J Immunol, 1995,25(12):3467-3473.
[131]FOOKS A R, JEEVARAJAH D, LEE J, et al. Oral or parenteral administration of replication-deficient adenoviruses expressing the measles virus haemagglutinin and fusion proteins:protective immune responses in rodents[J]. J Gen Virol,1998,79 (Pt 5):1027-1031.
[132]SANZ-PARRA A, JIMENEZ-CLAVERO M A, GARCIA-BRIONES M M, et al. Recombinant viruses expressing the foot-and-mouth disease virus capsid precursor polypeptide (P1) induce cellular but not humoral antiviral immunity and partial protection in pigs[J]. Virology,1999,259(1):129-134.
[133]MAYR G A, CHINSANGARAM J, GRUBMAN M J. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate[J]. Virology,1999,263(2):496-506.
[134]金宁一,张洪勇,尹革芬,等.共表达口蹄疫病毒衣壳蛋白前体P1-2A基因和蛋白酶3C基因重组鸡痘病毒的构建及其免疫原性[J].科学通报,2004(06).
[135]MA M, JIN N, SHEN G, et al. Immune responses of swine inoculated with a recombinant fowlpox virus co-expressing P12A and 3C of FMDV and swine IL-18[J]. Vet Immunol Immunopathol, 2008,121(1-2):1-7.
[136]刘明秋,牛晓峰,严维耀.以减毒猪霍乱沙门菌为载体的抗O型口蹄疫病毒重组活菌苗在家兔体内免疫应答的初步研究[J].Journal of Fudan University (Natural Science),2005,44(4):484-489.
[137]LI Y G, TIAN F L, GAO F S, et al. Immune responses generated by Lactobacillus as a carrier in DNA immunization against foot-and-mouth disease virus[J]. Vaccine,2007,25(5):902-911.
[138]李云岗,田夫林,王会波.以乳酸杆菌为载体的口蹄疫病毒VP1基因DNA疫苗猪体免疫试验 [J].中国兽医科学,2006,36(8)：601-605.
[139]MORGAN D O, MOORE D M. Protection of cattle and swine against foot-and-mouth disease, using biosynthetic peptide vaccines[J]. Am J Vet Res,1990,51(1):40-45.
[140]ZHANG H Y, SUN S H, GUO Y J, et al. Immune response in mice inoculated with plasmid DNAs containing multiple-epitopes of foot-and-mouth disease virus[J]. Vaccine,2003,21(32):4704-4707.
[141]WANG F, HE X W, JIANG L, et al. Enhanced immunogenicity of microencapsulated multiepitope DNA vaccine encoding T and B cell epitopes of foot-and-mouth disease virus in mice[J]. Vaccine, 2006,24(12):2017-2026.
[142]HU B, LI C, LU H, et al. Immune responses to the oral administration of recombinant Bacillus subtilis expressing multi-epitopes of foot-and-mouth disease virus and a cholera toxin B subunit[J]. J Virol Methods,201 1,171(1):272-279.
[143]FRANCIS M J, HASTINGS G Z, BROWN A L, et al. Immunological properties of hepatitis B core antigen fusion proteins[J]. Proc Natl Acad Sci U S A, 1990,87(7):2545-2549.
[144]PUMPENS P, GRENS E. HBV core particles as a carrier for B cell/T cell epitopes[J]. Intervirology, 2001,44(2-3):98-114.
[145]MILICH D R, PETERSON D L, SCHODEL F, et al. Preferential recognition of hepatitis B nucleocapsid antigens by Thl or Th2 cells is epitope and major histocompatibility complex dependent[J]. J Virol,1995,69(5):2776-2785.
[146]FEHR T, SKRASTINA D, PUMPENS P, et al. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles[J]. Proc Natl Acad Sci U S A, 1998,95(16):9477-9481.
[147]MILICH D R, CHEN M, SCHODEL F, et al. Role of B cells in antigen presentation of the hepatitis B core[J]. Proc Natl Acad Sci U S A, 1997,94(26):14648-14653.
[148]LAZDINA U, CAO T, STEINBERGS J, et al. Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B cells[J]. J Virol, 2001,75(14):6367-6374.
[149]PUMPENS P, GRENS E. Hepatitis B core particles as a universal display model:a structure-function basis for development[J]. FEBS Lett,1999,442(1):1-6.
[150]DE FILETTE M, MIN J W, BIRKETT A, et al. Universal influenza A vaccine:optimization of M2-based constructs[J]. Virology,2005,337(1):149-161.
[151]PUMPENS P, GRENS E. HBV core particles as a carrier for B cell/T cell epitopes[J]. Intervirology, 2001,44(2-3):98-114.
[152]YIN Y, ZHANG J, DONG D, et al. Chimeric hepatitis B virus core particles carrying an epitope of anthrax protective antigen induce protective immunity against Bacillus anthracis[J]. Vaccine, 2008,26(46):5814-5821.
[153]WANG Y S, OUYANG W, LIU X J, et al. Virus-like particles of hepatitis B virus core protein containing five mimotopes of infectious bursal disease virus (IBDV) protect chickens against IBDV[J]. Vaccine,2012,30(12):2125-2130.
[154]CHAMBERS M A, DOUG AN G, NEWMAN J, et al. Chimeric hepatitis B virus core particles as probes for studying peptide-integrin interactions[J]. J Virol,1996,70(6):4045-4052.
[155]ZHANG Y L, GUO Y J, WANG K. Y, et al. Enhanced immunogenicity of modified hepatitis B virus core particle fused with multiepitopes of foot-and-mouth disease virus[J]. Scand J Immunol, 2007,65(4):320-328.
[156]REN F, XU Y, MAO L, et al. Heat shock protein 110 improves the antitumor effects of the cytotoxic T lymphocyte epitope E7(49-57) in mice[J]. Cancer Biol Ther,2010,9(2):134-141.
[157]肖志军,张改平,杨汉春.传染性法氏囊病病毒VP2蛋白B细胞抗原表位免疫小鼠试验[J].华北农学报,2010,25(2)：233-235.
[158]宋幸辉,王睿,王选年.染性法氏囊病毒VP2蛋白抗原表位多肽P22的免疫原性及生物学功能鉴定[J].畜牧兽医学报,2011,42(5)：692-697.
[159]朱彦彩,王选年,银梅.His6免疫原的制备及免疫小鼠抗体效价检测[J].河南农业科学,2007,12：116-118.
[160]SHAO J J, WONG C K, LIN T, et al. Promising multiple-epitope recombinant vaccine against foot-and-mouth disease virus type O in swine[J]. Clin Vaccine Immunol,2011,18(1):143-149.
[161]DU Y, LI Y, HE H, et al. Enhanced immunogenicity of multiple-epitopes of foot-and-mouth disease virus fused with porcine interferon alpha in mice and protective efficacy in guinea pigs and swine[J]. J Virol Methods,2008,149(1):144-152.
[162]LI J, LI K N, GAO J, et al. Heat shock protein 70 fused to or complexed with hantavirus nucleocapsid protein significantly enhances specific humoral and cellular immune responses in C57BL/6 mice[J]. Vaccine,2008,26(25):3175-3187.
[163]CHAN E W, WONG H T, CHENG S C, et al. An immunoglobulin G based chimeric protein induced foot-and-mouth disease specific immune response in swine[J]. Vaccine,2000,19(4-5):538-546.
[164]YI J Z, LIU M Q, ZHU C Z, et al. Recombinant bivalent vaccine against foot-and-mouth disease virus serotype O/A infection in guinea pig[J]. Acta Biochim Biophys Sin (Shanghai),2004,36(9):589-596.
[165]ZENG W, HORROCKS K J, ROBEVSKA G, et al. A modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building[J]. J Biol Chem,2011,286(15):12944-12951.
[166]COBB A, ROBERTS L K, PALUCKA A K, et al. Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine[J]. J Immunol Methods,201 1,365(1-2):27-37.
[167]SOLANO-PARADA J, GONZALEZ-GONZALEZ G, TORRO L M, et al. Effectiveness of intranasal vaccination against Angiostrongylus costaricensis using a serine/threonine phosphatase 2 A synthetic peptide and recombinant antigens[J]. Vaccine,2010,28(32):5185-5196.
[168]PAHAR B, CANTU M A, ZHAO W, et al. Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV[J]. Vaccine, 2006,24(47-48):6839-6849.
[169]SONG H, WANG Z, ZHENG D, et al. A novel mucosal vaccine against foot-and-mouth disease virus induces protection in mice and swine[J]. Biotechnol Lett,2005,27(21):1669-1674.
[170]WANG G, PAN L, ZHANG Y, et al. Intranasal delivery of cationic PLGA nano/microparticles-loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge[J]. PLoS One,2011,6(11):e27605.
[171]王潇,王志钢,杜瑞平.白细胞介素-10分子佐剂增强口蹄疫DNA疫苗黏膜免疫效果研究[J].中国农业科学,2011(14)：3045-3052.
[172]CHALLA S, SZCZEPANEK S M, ROOD D, et al. Bacterial Toxin Fusion Proteins Elicit Mucosal Immunity against a Foot-and-Mouth Disease Virus Antigen When Administered Intranasally to Guinea Pigs[J]. Adv Virol,2011,2011:713769.
[173]MORGAN D O, MOORE D M. Protection of cattle and swine against foot-and-mouth disease, using biosynthetic peptide vaccines[J]. Am J Vet Res,1990,51(1):40-45.
[174]BROWN F, BENKIRANE N, LIMAL D, et al. Delineation of a neutralizing subregion within the immunodominant epitope (GH loop) of foot-and-mouth disease virus VP1 which does not contain the RGD motif[J]. Vaccine,1999,18(1-2):50-56.
[175]CARR B V, LEFEVRE E A, WINDSOR M A, et al. CD4+ T-cell responses to foot-and-mouth disease virus in vaccinated cattle[J]. J Gen Virol,2013,94(Pt 1):97-107.
[176]COLLEN T, DIMARCHI R, DOEL T R. A T cell epitope in VP1 of foot-and-mouth disease virus is immunodominant for vaccinated cattle[J]. J Immunol,1991,146(2):749-755.
[177]BLANCO E, GARCIA-BRIONES M, SANZ-PARRA A, et al. Identification of T-cell epitopes in nonstructural proteins of foot-and-mouth disease virus[J]. J Virol,2001,75(7):3164-3174.
[178]CIANGA P, MEDESAN C, RICHARDSON J A, et al. Identification and function of neonatal Fc receptor in mammary gland of lactating mice[J]. Eur J Immunol,1999,29(8):2515-2523.
[179]郭德军,柳增善.黑曲霉GA Ⅰ基因的克隆及在P.pastoris中的分泌表达[J].黑龙江八一农垦大学学报,2005,17(4)：69-72.
[180]FABER K N, HARDER W, AB G, et al. Review:methylotrophic yeasts as factories for the production of foreign proteins[J]. Yeast,1995,11(14):1331-1344.
[181]ZHANG Y, LIU X, WANG M. Cloning, expression, and characterization of two novel cuticle-degrading serine proteases from the entomopathogenic fungus Cordyceps sinensis[J]. Res Microbiol,2008,159(6):462-469.
[182]DOEL T R, COLLEN T. Qualitative assessment of 146 S particles of foot-and-mouth disease virus in preparations destined for vaccines[J]. J Biol Stand,1982,10(2):69-81.
[183]WANG J L, LIU M Q, HAN J, et al. A peptide of foot-and-mouth disease virus serotype Asial generating a neutralizing antibody response, and an immunostimulatory peptide[J]. Vet Microbiol, 2007,125(3-4):224-231.
[184]KLEID D G, YANSURA D, Small B, et al. Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swine[J]. Science,1981,214(4525):1125-1129.
[185]MILICH D R, PETERSON D L, SCHODEL F, et al. Preferential recognition of hepatitis B nucleocapsid antigens by Thl or Th2 cells is epitope and major histocompatibility complex dependent[J]. J Virol,1995,69(5):2776-2785.
[186]FEHR T, SKRASTINA D, PUMPENS P, et al. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles[J]. Proc Nat] Acad Sci U S A, 1998,95(16):9477-9481.
[187]MILICH D R, CHEN M, SCHODEL F, et al. Role of B cells in antigen presentation of the hepatitis B core[J]. Proc Natl Acad Sci U S A, 1997,94(26):14648-14653.
[188]PRATO M M, FORSYTH M A, BELSHAM G J, et al. Localization of foot-and-mouth disease virus RNA by in situ hybridization within bovine tissues[J]. Virus Res,1999,62(1):67-76.
[189]HOLMGREN J, CZERKINSKY C, ERIKSSON K, et al. Mucosal immunisation and adjuvants:a brief overview of recent advances and challenges[J]. Vaccine,2003,21 Suppl 2:S89-S95.
[190]XU W, SHEN Y, JIANG Z, et al. Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection[J]. Vaccine,2004,22(27-28):3603-3612.
[191]KWEON M N. Sublingual mucosa:A new vaccination route for systemic and mucosal immunity[J]. Cytokine,2011,54(1):1-5.
[192]GREENBAUM E, ENGELHARD D, LEVY R, et al. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine[J]. Vaccine,2004,22(20):2566-2577.
[193]FISCHER D, ROOD D, BARRETTE R W, et al. Intranasal immunization of guinea pigs with an immunodominant foot-and-mouth disease virus peptide conjugate induces mucosal and humoral antibodies and protection against challenge[J]. J Virol,2003,77(13):7486-7491.
[194]BRANDTZAEG P. Induction of secretory immunity and memory at mucosal surfaces[J]. Vaccine, 2007,25(30):5467-5484.
[195]ERIKSSON K, HOLMGREN J. Recent advances in mucosal vaccines and adjuvants[J]. Curr Opin Immunol,2002,14(5):666-672.
[196]郝生宏,杨荣芳.黏膜免疫[J].营养与疾病,2004(4)：42-44.
[197]SHAH U, DICKINSON B L, BLUMBERG R S, et al. Distribution of the IgG Fc receptor, FcRn, in the human fetal intestine[J]. Pediatr Res,2003,53(2):295-301.
[198]ZHU X, MENG G, DICKINSON B L, et al. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells[J]. J Immunol, 2001,166(5):3266-3276.
[199]STIRLING C M, CHARLESTON B, TAKAMATSU H, et al. Characterization of the porcine neonatal Fc receptor--potential use for trans-epithelial protein delivery[J]. Immunology,2005,114(4):542-553.
[200]MAYER B, KIS Z, KAJAN G, et al. The neonatal Fc receptor (FcRn) is expressed in the bovine lung[J]. Vet Immunol Immunopathol,2004,98(1-2):85-89.
[201]OBER R J, RADU C G, GHETIE V, et al. Differences in promiscuity for anlibody-FcRn interactions across species:implications for therapeutic antibodies[J]. Int Immunol,2001,13(12):1551-1559.
[202]NEUTRA M R, KOZLOWSKI P A. Mucosal vaccines:the promise and the challenge[J]. Nat Rev Immunol,2006,6(2):148-158.
[203]HOLMGREN J, CZERKINSKY C. Mucosal immunity and vaccines[J]. Nat Med,2005,11(4 Suppl):S45-S53.
[204]GALLICHAN W S, ROSENTHAL K L. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization[J]. J Infect Dis,1998,177(5):1155-1161.
[205]MESTECKY J, RUSSELL M W, ELSON C O. Perspectives on mucosal vaccines:is mucosal tolerance a barrier?[J]. J Immunol,2007,179(9):5633-5638.